% Created 2022-01-06 Thu 13:27
% Intended LaTeX compiler: pdflatex
\documentclass[12pt]{scrartcl}
\usepackage[utf8]{inputenc}
\usepackage[T1]{fontenc}
\usepackage{graphicx}
\usepackage{longtable}
\usepackage{wrapfig}
\usepackage{rotating}
\usepackage[normalem]{ulem}
\usepackage{amsmath}
\usepackage{amssymb}
\usepackage{capt-of}
\usepackage{hyperref}
\hypersetup{colorlinks,linkcolor=black,urlcolor=blue}
\usepackage{textpos}
\usepackage{textgreek}
\usepackage[version=4]{mhchem}
\usepackage{chemfig}
\usepackage{siunitx}
\usepackage{gensymb}
\usepackage[usenames,dvipsnames]{xcolor}
\usepackage{lmodern}
\usepackage{verbatim}
\usepackage{tikz}
\usepackage{wasysym}
\usetikzlibrary{shapes.geometric,arrows,decorations.pathmorphing,backgrounds,positioning,fit,petri}
\usepackage[automark, autooneside=false, headsepline]{scrlayer-scrpage}
\clearpairofpagestyles
\ihead{\leftmark}% section on the inner (oneside: right) side
\ohead{\rightmark}% subsection on the outer (oneside: left) side
\addtokomafont{pagehead}{\upshape}% header upshape instead of italic
\ofoot*{\pagemark}% the pagenumber in the center of the foot, also on plain pages
\pagestyle{scrheadings}
\author{Matthew Henderson, PhD, FCACB}
\date{\today}
\title{Energy Metabolism}
\hypersetup{
 pdfauthor={Matthew Henderson, PhD, FCACB},
 pdftitle={Energy Metabolism},
 pdfkeywords={},
 pdfsubject={},
 pdfcreator={Emacs 27.2 (Org mode 9.5)}, 
 pdflang={English}}
\begin{document}

\maketitle
\setcounter{tocdepth}{2}
\tableofcontents


\setchemfig{atom style={scale=0.75}}

\section{Mitochondrial Redox Rxns}
\label{sec:orge6ae08a}
\subsection{Cellular Redox State}
\label{sec:org189bba0}
\begin{itemize}
\item NADH and FADH\textsubscript{2} are reducing agents
\begin{itemize}
\item loose electron(s) (oxidized) in a reduction rxn
\item \ce{NADH <=>[Ox][Red] NAD+ + H}
\item \ce{FADH2 <=>[Ox][Red] FAD + 2H}
\end{itemize}
\item \(\downarrow\) cellular respiration results in:
\begin{itemize}
\item \(\uparrow\) NADH \& FADH\textsubscript{2} \(\because\) not oxdized by ETC
\item \(\uparrow\) lactate:pyruvate \(\because\) \(\uparrow\) NADH
\item \(\uparrow\) \(\beta\)-hydroxybutyrate  \(\because\) \(\uparrow\) NADH
\end{itemize}

\item PDHC deficiency: N/\(\downarrow\) L:P < 25
\begin{itemize}
\item \(\because\) \(\downarrow\) TCA \(\therefore\) \(\downarrow\) NADH
\end{itemize}
\item ETC deficiency: \(\uparrow\) L:P > 25
\begin{itemize}
\item \(\because\) \(\uparrow\) NADH
\end{itemize}
\end{itemize}

\subsection{Pyruvate Redox Rxns}
\label{sec:org7f8f9e0}

\begin{description}
\item[{pyruvate dehydrogenase complex}] pyruvate is oxidized \(\to\) acetyl-CoA
\end{description}

\ce{pyruvate + CoA + NAD+ <=>[PDHC] acetyl-CoA + CO2 + NADH + H+}

\begin{description}
\item[{lactate dehydrogenase}] pyruvate is reduced \(\to\) lactate
\end{description}

\ce{pyruvate + NADH <=>[LDH] lactate + NAD+}

\begin{itemize}
\item normal lactate/pyruvate < 20
\end{itemize}

\subsection{TCA Net Reaction}
\label{sec:org52f2e4f}
\begin{description}
\item[{net reaction}] acetyl-CoA oxidized to 2CO\textsubscript{2}
\item[{net reaction}] 3 NAD\textsuperscript{+} reduced to 3 NADH
\item[{net reaction}] FAD reduced to FADH\textsubscript{2}
\end{description}
{\scriptsize\ce{acetyl-CoA + 3NAD+ + FAD + GDP + Pi + 2H2O -> 2CO2 + CoA + 3NADH + FADH2 + GTP + 2H+}}

\subsection{ETC Redox Rxns}
\label{sec:org03cb0ba}
\begin{description}
\item[{Complex I}] NADH oxidized to NAD\textsuperscript{+}
\end{description}

\ce{NADH <=>[CI] NAD+ + H}

\begin{description}
\item[{ETF/ETF-QO}] FADH\textsubscript{2} oxidized to FAD

\ce{FADH2 <=>[ETF/ETF-CO] FAD + 2H+}
\end{description}

\subsection{Ketone Redox Rxn}
\label{sec:org0625175}
\begin{description}
\item[{hydroxybutyrate dehydrogenase}] acetoacetate reduced to \(\beta\)-hydroxybutyrate

\ce{acetoacetate + NADH <=>[HBDH] \beta-hydroxybutyrate + NAD+}
\end{description}

\section{Fatty Acid Oxidation}
\label{sec:org16f1c05}
\subsection{Introduction}
\label{sec:org281aa37}
\begin{itemize}
\item fatty acids are usually straight aliphatic chains with a methyl
group at one end (\(\omega\)-carbon) and a carboxyl group at the other
end
\end{itemize}

\definesubmol{x}{-[1,.6]-[7,.6]}
\definesubmol{a}{-[1,.6]\beta{}-[7,.6]\alpha{}}
\definesubmol{y}{!x!x!x!x!x!x!x!x}
\definesubmol{b}{!x!x!x!x!x!x!x!a}
%\chemfig{H{_3}C!y-[1]C(=[1]O)-[7]O{^-}}
\begin{center}
\chemname{\chemfig{\omega{}!b-[1]C(=[1]O)-[7]O{^-}}}{stearic acid 18:0}
\end{center}

\begin{itemize}
\item non-systematic historical names most commonly used
\begin{description}
\item[{palmitic acid}] C16:0 discovered in palm oil
\item[{stearic acid}] C18:0 from the Greek word "stear" which means tallow
\item[{oleic acid}] C18:1 oleic means derived from olive oil
\end{description}
\item position of a double bond is designated by the number of the carbon in the double bond that is closest to the carboxyl group
\end{itemize}

\definesubmol{x}{-[1,.6]-[7,.6]}
\definesubmol{y}{-[7,.6]-[1,.6]}
\definesubmol{d}{=[0,.6](-[7,0.25,,,draw=none]\scriptstyle\color{red}9)-[1,.6]}
\definesubmol{e}{!x!x!x!x!d!y!y!y}
\begin{center}
\chemname{\chemfig{\omega{}(-[3,0.25,,,draw=none]\scriptstyle\color{red}18)!e(-[2,0.25,,,draw=none]\scriptstyle\color{red}2)-[7,.6]COOH}}{\small Oleic acid 18:1,\Delta{}$^9$}
\end{center}
\begin{itemize}
\item oleic acid - 18:1,\(\Delta\)\textsuperscript{9}
\begin{itemize}
\item 18:1 - 18 carbons and 1 double bond
\item \(\Delta\)\textsuperscript{9} - double bond between 9th and 10th carbon
\begin{itemize}
\item also 18:1(9)
\item distance from \(\omega\) methyl group, \(\omega\)-9
\end{itemize}
\end{itemize}

\item fatty acid chain length:
\begin{description}
\item[{very long-chain}] > C20
\item[{long-chain}] C12-C20
\item[{medium-chain}] C6-C12
\item[{short-chain}] C4
\end{description}
\end{itemize}

\subsubsection{Mitochondrial Fatty Acid \(\beta\)-oxidation}
\label{sec:org1967b84}
\begin{itemize}
\item involves three processes (Figure \ref{fig:org6a42069})
\begin{enumerate}
\item entry of fatty acids into mitochondria
\begin{itemize}
\item long-chain fatty acids are activated to fatty-acyl coenzyme A (CoA) esters
in the cytoplasm
\item need to be transferred to carnitine to cross the inner
mitochondrial membrane
\item transferred back to CoA within the mitochondria
\item CPT I is the main site for the regulation of fatty acid
oxidation
\begin{itemize}
\item inhibited by cytoplasmic malonyl-CoA
\end{itemize}
\item medium and short-chain fatty acids enter mitochondria
independent of carnitine and are activated to CoA esters in the
matrix
\end{itemize}
\item \(\beta\)-oxidation via a spiral pathway (Figure \ref{fig:orgf2ab93a})
\begin{itemize}
\item the \(\alpha\) carbon is right beside a functional group, and the
\(\beta\) carbon is the next one over
\begin{itemize}
\item \(\therefore\) the second carbon from the thioester (\(\beta\)-carbon) is where
\(\beta\)-oxidation occurs
\end{itemize}
\item reactions are as follows:
\begin{enumerate}
\item fatty acyl-CoA molecule is first dehydrogenated between the \(\alpha\)
and the \(\beta\) carbon atoms by acyl-CoA dehydrogenase (Table \ref{tab:orgb4d806f})
\begin{itemize}
\item FAD accepts the hydrogen abstracted and is reduced to FADH\textsubscript{2}
\item yields 2-trans-enoyl-CoA
\end{itemize}
\item trans double bond just created is hydrated by enoyl-CoA
hydratase, which yields hydroxyacyl-CoA
\begin{itemize}
\item \(\alpha\) carbon is now once more fully reduced
\end{itemize}
\item \(\beta\)-hydroxyl group is converted to a keto group by
hydroxyacyl-CoA dehydrogenase
\begin{itemize}
\item NAD\textsuperscript{+} accepts the hydrogen
\item product is \(\beta\)-ketoacyl-CoA
\end{itemize}
\item thiolase introduces a new molecule of coenzyme A to cleave
the \(\beta\)-ketoacyl-CoA, which releases acetyl-CoA and a new,
shortened acyl-CoA that enters the next cycle of
\(\beta\)-oxidation
\end{enumerate}
\item the process is repeated until the fatty acid is completely
broken down
\item acyl chains with even numbers of carbons, this will yield
acetyl-CoA only, those with odd numbers of carbons will yield
one molecule of propionyl-CoA in the final thiolase step
\end{itemize}
\item electron transfer
\begin{itemize}
\item electrons are passed to the respiratory chain either directly
(from NADH to complex I) or via two transfer proteins (from
FADH\textsubscript{2} to ubiquinone)
\end{itemize}
\end{enumerate}
\end{itemize}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.9\textwidth]{fao/figures/b_oxidation.png}
\caption{\label{fig:org6a42069}Fatty Acid \(\beta\)-Oxidation}
\end{figure}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.9\textwidth]{fao/figures/Slide12.png}
\caption{\label{fig:org068a5fd}Fatty Acid \(\beta\)-Oxidation and Ketone Body Metabolism}
\end{figure}


\begin{figure}[htbp]
\centering
\includegraphics[width=0.9\textwidth]{fao/figures/boxl.png}
\caption{\label{fig:orgf2ab93a}Fatty Acid \(\beta\)-Oxidation}
\end{figure}



\begin{table}[htbp]
\caption{\label{tab:orgb4d806f}Acyl-CoA Dehydrogenases: Chain Length Specificity}
\centering
\begin{tabular}{lrl}
Enzyme & Length & location\\
\hline
VLCAD & 14-20 & IMM\\
LCAD & 12-18 & MM\\
MCAD & 6-12 & MM\\
SCAD & 2-6 & MM\\
\end{tabular}
\end{table}

\subsubsection{Common Manifestations in FAODs}
\label{sec:org36b48e2}
\begin{itemize}
\item fasting hypoglycaemia is the classic metabolic disturbance in FAODs
\begin{itemize}
\item primarily due to increased peripheral glucose consumption
\item hepatic glucose output is also reduced under some conditions
\end{itemize}
\item hypoglycaemia is hypoketotic
\begin{itemize}
\item ketone bodies can be synthesised
\begin{itemize}
\item from medium-or short-chain FAs (depending on the defect)
\item or if there is high residual enzyme activity
\item plasma concentrations are lower than expected for hypoglycaemia or the plasma free fatty acid concentrations
\end{itemize}
\end{itemize}
\item hyperammonaemia occurs in some severe defects
\begin{itemize}
\item with normal or low glutamine concentrations
\item \textbf{decreased acetyl-CoA production reducing the synthesis of N-acetylglutamate (NAG)}
\end{itemize}
\item lactic acidaemia is seen in long-chain FAODs (LCHAD and MTP deficiencies)
\begin{itemize}
\item inhibitory effects of metabolites on PDH
\end{itemize}
\item moderate hyperuricaemia - frequent finding during acute attacks
\item secondary hyperprolinaemia occurs in some babies with MAD deficiency (GA2)
\item accumulating long-chain acylcarnitines may be responsible for
arrhythmias and may interfere with surfactant metabolism
\item in LCHAD and MTP deficiencies, long chain hydroxy-acylcarnitine
concentrations correlate with the severity of retinopathy and may
cause both this and the peripheral neuropathy
\end{itemize}
\begin{itemize}
\item summarized in table \ref{tab:org52aef3f}
\end{itemize}

\begin{table}[htbp]
\caption{\label{tab:org52aef3f}Common Manifestations in FAODs}
\centering
\begin{tabular}{llllll}
FAOD & sudden & fasting & skeletal & cardio- & liver\\
 & death & intolerance & myopathy & myopathy & disease\\
\hline
CUD & \(\Uparrow\) & \(\uparrow\) & \(\uparrow\) & \(\Uparrow\) & \(\uparrow\)\\
CPTI & \(\uparrow\) & \(\Uparrow\) & rare & rare & \(\uparrow\)\\
CACT & \(\uparrow\) & \(\Uparrow\) & \(\uparrow\) & \(\Uparrow\) & \(\uparrow\)\\
CPTII & rare & rare & \(\Uparrow\) & rare & rare\\
VLCAD & \(\Uparrow\) & \(\Uparrow\) & \(\uparrow\) & \(\Uparrow\) & \(\uparrow\)\\
GAII & \(\uparrow\) & \(\uparrow\) & \(\uparrow\) & \(\uparrow\) & \(\uparrow\)\\
LCHAD & \(\Uparrow\) & \(\Uparrow\) & \(\uparrow\) & \(\Uparrow\) & \(\Uparrow\)\\
TFP & \(\Uparrow\) & \(\Uparrow\) & \(\uparrow\) & \(\Uparrow\) & \(\Uparrow\)\\
MCAD & \(\Uparrow\) & \(\Uparrow\) & rare & rare & \(\Uparrow\)\\
\end{tabular}
\end{table}

\subsection{Carnitine Cycle Defects}
\label{sec:orgff27fe6}
\begin{itemize}
\item carnitine-mediated transport of fatty acids is the rate-limiting
step in the oxidation of fats
\item defect anywhere in the pathway leads to inadequate formation of
ketone bodies in response to fasting along with inadequate
gluconeogenesis and hypoglycemia
\end{itemize}

\subsubsection{Carnitine Uptake Deficiency}
\label{sec:org1eb837d}
\begin{itemize}
\item AKA Primary Carnitine Deficiency, Carnitine Transporter Deficiency
\end{itemize}
\begin{enumerate}
\item Clinical Presentation
\label{sec:org27bafef}
\begin{itemize}
\item cardiomyopathy, cardiac failure, muscle weakness, liver disease
\item precipitated by infection, fasting, pregnancy or antibiotics containing pivalate
\begin{itemize}
\item pivalate is excreted bound to carnitine \(\to\) \(\downarrow\) carnitine concentration
\begin{itemize}
\item isobaric with C5-carnitine
\end{itemize}
\end{itemize}
\item some present in infancy with hypoglycaemia, liver dysfunction and hyperammonaemia
\item other children develop heart failure due to cardiomyopathy,
thickened ventricular walls and reduced contractility
\item often accompanied by skeletal muscle weakness
\item adults may suffer fatigue or arrhythmias
\item screening has shown that many subjects with low plasma carnitine remain asymptomatic
\end{itemize}
\item Metabolic Derangement
\label{sec:org3273e42}
\begin{itemize}
\item \textbf{organic cation/carnitine transporter (OCTN2)} responsible for
carnitine uptake
\item defects \(\to\) primary carnitine deficiency with \(\uparrow\) renal loss of carnitine
\begin{itemize}
\item \(\downarrow\) plasma carnitine concentrations
\item \(\downarrow\) intracellular carnitine concentrations \(\to\) impair fatty acid
oxidation
\end{itemize}
\end{itemize}

\item Genetics
\label{sec:orgdc09181}
\begin{itemize}
\item AR OCTN2
\end{itemize}
\item Diagnostic Tests
\label{sec:org3cbe8af}
\begin{itemize}
\item \(\Downarrow\) plasma total carnitine \textless{} 5\% of normal
\item \(\downarrow\) plasma free carnitine
\item \(\uparrow\) urine free carnitine
\end{itemize}
\item Treatment
\label{sec:org04c9dbc}
\begin{itemize}
\item carnitine supplementation
\end{itemize}
\end{enumerate}
\subsubsection{Carnitine Palmitoyltransferase I Deficiency}
\label{sec:orgb90c83d}
\begin{enumerate}
\item Clinical Presentation
\label{sec:org1ebc152}
\begin{itemize}
\item usually present by the age of 2 years with hypoketotic hypoglycaemia
\begin{itemize}
\item induced by fasting or illness
\end{itemize}
\item accompanied by hepatomegaly, liver dysfunction and occasionally cholestasis
\begin{itemize}
\item may also be transient lipaemia and renal tubular acidosis
\end{itemize}
\end{itemize}
\item Metabolic Derangement
\label{sec:org3361c78}
\begin{itemize}
\item \textbf{carnitine palmitoyltransferase I (CPT1)} is responsible for the
formation of acylcarnitines
\begin{itemize}
\item catalyzes transfer of the acyl group of a long-chain fatty
acyl-CoA from CoA to carnitine
\item allows for subsequent movement of the acylcarnitine from the
cytosol into the intermembrane space of mitochondria
\end{itemize}
\item \textbf{CPTIa} liver and kidney
\item \textbf{CPTIb}  muscle and heart
\item \textbf{CPTIc}  brain
\item only CPTIa deficiency has been identified
\item medium chain and short chain fatty acids pass directly into
mitochondria and do not require esterification with carnitine
\end{itemize}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.6\textwidth]{fao/figures/cpt1.png}
\caption{\label{fig:orgae386da}CPT1 (OMM) \& CPTII (IMM)}
\end{figure}

\item Genetics
\label{sec:orgcef8e8d}
\begin{itemize}
\item AR CPT1A
\item CPTI deficiency is extremely common in the Inuit population of Canada and Greenland
\begin{itemize}
\item P479L
\end{itemize}
\item a few of these patients present with hypoglycaemia as neonates or young children
\begin{itemize}
\item most remain asymptomatic
\end{itemize}
\end{itemize}
\item Diagnostic Tests
\label{sec:org4964646}
\begin{itemize}
\item \(\uparrow\) total/free carnitine
\item \(\uparrow\) C0
\item \(\downarrow\) C16, C18, C18:1
\end{itemize}
\item Treatment
\label{sec:orgd727508}
\begin{itemize}
\item prevent hypoglycaemia
\item low-fat diet
\item medium-chain triglycerides to provide \(\sim\) 1/3 total calories
\begin{itemize}
\item C6-C10 fatty acids do not require the carnitine shuttle for entry
into mitochondria
\end{itemize}
\end{itemize}
\end{enumerate}
\subsubsection{Carnitine Acylcarnitine Translocase Deficiency}
\label{sec:orge8d725d}
\begin{enumerate}
\item Clinical Presentation
\label{sec:org9bf0aac}
\begin{itemize}
\item rare disorder usually presents in the neonatal period, with
death by 3 months of age
\begin{itemize}
\item severe hypoglycaemia and hyperammonaemia, cardiomyopathy,
atrioventricular block and ventricular arrhythmias
\end{itemize}
\item few more mildly affected patients present later with hypoglycaemic
encephalopathy
\begin{itemize}
\item precipitated by fasting or infections
\end{itemize}
\end{itemize}
\item Metabolic Derangement
\label{sec:org30fe363}
\begin{itemize}
\item \textbf{carnitine-acylcarnitine translocase (CACT)} catalyzes the transfer
of the acylcarnitines across the inner mitochondrial membrane
(Figure \ref{fig:org4b48f7a})
\begin{itemize}
\item acylcarnitine in
\item carnitine out
\end{itemize}
\item deficiency of carnitine acyl translocase leads to the accumulation
of the free fatty acids outside the mitochondrial matrix
\item long chain acylcarnitines and short chains are also found, because
translocase catalyzes the transport of short as well as long chain
acylcarnitines
\item \(\Uparrow\) long chain acyl carnitines during illness and fasting
induced lipolysis
\item \(\uparrow\) medium and short chain esters might reflect the acyl CoA products
of peroxisomal oxidation that would require transfer into the
mitochondria via the translocase for final oxidation
\item secondary deficiency of free carnitine would be expected to result
from the excretion over time of large amounts of esterified
carnitine
\end{itemize}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.6\textwidth]{fao/figures/translocase.png}
\caption{\label{fig:org4b48f7a}Carnitine Acylcarnitine Translocase}
\end{figure}

\item Genetics
\label{sec:org8310fa0}
\begin{itemize}
\item AR SLC25A20
\end{itemize}
\item Diagnostic Tests
\label{sec:orgb4a42e4}
\begin{itemize}
\item \(\Downarrow\) total carnitine
\item \(\downarrow\) C0
\item \(\Uparrow\) C16, C18, C18:1
\end{itemize}
\item Treatment
\label{sec:org35c4f84}
\begin{itemize}
\item prevent hypoglycaemia
\item low-fat diet
\end{itemize}
\end{enumerate}
\subsubsection{Carnitine Palmitoyltransferase II Deficiency}
\label{sec:org78cbadd}
\begin{enumerate}
\item Clinical Presentation
\label{sec:orgf9f86a3}
\begin{enumerate}
\item Neonatal
\label{sec:orgda1671d}
\begin{itemize}
\item severe neonatal onset CPT II deficiency is usually lethal
\item patients become comatose within a few days of birth
\begin{itemize}
\item hypoglycaemia and hyperammonaemia
\item may have cardiomyopathy, arrhythmias and congenital malformations,
principally renal cysts and neuronal migration defects
\end{itemize}
\item an intermediate form of CPT II deficiency causes episodes of
hypoglycaemia and liver dysfunction, sometimes accompanied by
cardiomyopathy and arrhythmias
\end{itemize}

\item Childhood
\label{sec:org3a77a7a}
\begin{itemize}
\item episodes may be brought on by infections or exercise
\item moderate or severe episodes with myoglobinuria \& \(\uparrow\) CK
\begin{itemize}
\item may lead to acute renal failure
\item CK often normalises between episodes but may remain moderately
elevated
\end{itemize}
\end{itemize}

\item Adolescence and Adult
\label{sec:org5fe4d6b}
\begin{itemize}
\item most common form is a partial deficiency that presents with
episodes of rhabdomyolysis
\begin{itemize}
\item usually precipitated by prolonged exercise
\item particularly in the cold or after fasting
\end{itemize}
\end{itemize}
\end{enumerate}

\item Metabolic Derangement
\label{sec:org5469d6b}
\begin{itemize}
\item \textbf{carnitine palmitoyltransferase II (CPTII)} is situated on the inner
mitochondrial membrane, catalyzes the regeneration of carnitine and
the long chain fatty acyl CoAs, which then undergo \(\beta\)-oxidation
(Figure \ref{fig:orgae386da})
\end{itemize}
\item Genetics
\label{sec:orgddeb5f4}
\begin{itemize}
\item AR CPT2
\end{itemize}
\item Diagnostic Tests
\label{sec:org0a95373}
\begin{itemize}
\item \(\downarrow\) total carnitine
\item \(\uparrow\) (C16 + C18)/C2
\item \(\uparrow\) CK
\item \(\uparrow\) urine myoglobin
\end{itemize}
\item Treatment
\label{sec:orge7c7460}
\begin{itemize}
\item high-carbohydrate (70\%) and low-fat (<20\%) diet to provide fuel for glycolysis
\item carnitine to convert potentially toxic long-chain acyl-CoAs to
acylcarnitines
\end{itemize}
\end{enumerate}
\subsection{\(\beta\)-Oxidation Defects}
\label{sec:org4c9326e}
\subsubsection{Very-Long-Chain Acyl-CoA Dehydrogenase Deficiency}
\label{sec:org431002a}
\begin{enumerate}
\item Clinical Presentation
\label{sec:org9a00dce}
\begin{enumerate}
\item Infancy
\label{sec:org586b304}
\begin{itemize}
\item severely affected patients present in early infancy with
cardiomyopathy in addition to the problems seen in milder patients
\end{itemize}
\item Childhood
\label{sec:org84273d3}
\begin{itemize}
\item liver dysfunction, hepatomegaly
\item patients present in childhood with hypoglycaemia but suffer exercise
or illness induced rhabdomyolysis or chronic weakness at a later age
\end{itemize}
\item Adolescence and Adult
\label{sec:orgdbbd662}
\begin{itemize}
\item mildly affected patients present as adolescents or adults with
exercise-induced rhabdomyolysis
\end{itemize}
\end{enumerate}
\item Metabolic Derangement
\label{sec:org14b64db}
\begin{itemize}
\item \textbf{very-long-chain acyl-coa dehydrogenase (VLCAD)} is one of four
mitochondrial acyl-CoA-dehydrogenases that catalyze the initial
steps in the \(\beta\)-oxidation of fatty acids (Table \ref{tab:orgb4d806f})
\item optimal substrate is C16-CoA (palmitoy-CoA)
\item ACAD9 is responsible for production of C14:1-carnitine and
C12-carnitine in VLCAD deficiency
\end{itemize}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.6\textwidth]{fao/figures/vlcad.png}
\caption{\label{fig:org812a82c}VLCAD Reaction}
\end{figure}

\item Genetics
\label{sec:orgc70fdb2}
\begin{itemize}
\item AR ACADVL
\end{itemize}

\item Diagnostic Tests
\label{sec:org133fd10}
\begin{itemize}
\item \(\uparrow\) C14:1
\item \(\uparrow\) C14:1/C12:1
\item \(\uparrow\) UOA C3-C14 dicarboxylic acids
\end{itemize}
\item Treatment
\label{sec:org5b1030c}
\begin{itemize}
\item avoid fasting
\item more severe forms low-fat diet with MCT
\end{itemize}
\end{enumerate}

\subsubsection{Mitochondrial Trifunctional Protein Deficiency}
\label{sec:org268c28c}
\begin{enumerate}
\item Clinical Presentation
\label{sec:org15c1b63}
\begin{itemize}
\item presentation of generalised MTP deficiency is heterogeneous
\item patients with severe deficiency present as neonates
\begin{itemize}
\item cardiomyopathy, respiratory distress, hypoglycaemia and liver dysfunction
\item most die within a few months, regardless of treatment
\end{itemize}
\item other patients resemble those with isolated LCHAD deficiency
\item milder neuromyopathic phenotype:
\begin{itemize}
\item exercise induced rhabdomyolysis and progressive peripheral
neuropathy
\item can present at any age from infancy to adulthood
\end{itemize}
\item mothers who are heterozygous for LCHAD or MTP deficiency have a high
risk of illness during pregnancies when carrying an affected fetus
\begin{itemize}
\item HELLP syndrome (Haemolysis, Elevated Liver enzymes and Low Platelets)
\item acute fatty liver of pregnancy (AFLP)
\end{itemize}
\end{itemize}
\item Metabolic Derangement
\label{sec:org699ff82}
\begin{itemize}
\item MTP a hetero-octamer composed of four \(\alpha\)-subunits and four
\(\beta\)-subunits
\item \(\alpha\)-subunit encoded by HADHA has long-chain enoyl-CoA hydratase
(LCEH) and long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD)
activities
\item \(\beta\)-subunit encoded by HADHB has long-chain ketoacyl-CoA thiolase
(LCKAT) activity
\item MTP deficiency is characterized by decreased activity of all 3 enzymes
\begin{itemize}
\item can result from mutations that affect the assembly of and/or
degradation of the hetero-octomeric holoenzyme
\end{itemize}
\end{itemize}

\item Genetics
\label{sec:org795f409}
\begin{itemize}
\item AR HADHA, HADHB
\end{itemize}

\item Diagnostic Tests
\label{sec:orgb9d01b8}
\begin{itemize}
\item plasma acylcarnitines and UOA similar to LCHAD
\item \(\uparrow\) lactate \(\because\) 3-OH-palmitoyl-CoA inhibits PDH
\item \(\uparrow\) hydroxy-acylcarnitines
\begin{itemize}
\item \(\uparrow\) C14OH, C16OH, C18OH, C18:1OH
\end{itemize}
\item \(\uparrow\) UOA C6-C14 dicarboxylic and hydroxy-dicarboxylic acids
\item molecular
\end{itemize}

\item Treatment
\label{sec:org6561960}
\begin{itemize}
\item avoid fasting
\item low fat diet with MCT
\end{itemize}
\end{enumerate}

\subsubsection{Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase}
\label{sec:org83f1eb6}
\begin{enumerate}
\item Clinical Presentation
\label{sec:orged3345d}
\begin{itemize}
\item isolated LCHAD deficiency usually presents acutely before 6 months of age
\begin{itemize}
\item hypoglycaemia, liver dysfunction, lactic acidosis
\item many have cardiomyopathy, some have hypoparathyroidism or ARDS
\end{itemize}
\item others present with chronic symptoms
\begin{itemize}
\item failure to thrive, hypotonia, occasionally cholestasis or cirrhosis
\end{itemize}
\item episodes of rhabdomyolysis are common
\item many develop retinopathy, may start as early as 2 years of age
\begin{itemize}
\item granular pigmentation followed by chorioretinal atrophy w deteriorating central vision
\item some develop cataracts
\end{itemize}
\item mothers who are heterozygous for LCHAD or MTP deficiency have a high
risk of illness during pregnancies when carrying an affected fetus
\begin{itemize}
\item HELLP syndrome (Haemolysis, Elevated Liver enzymes and Low Platelets)
\item acute fatty liver of pregnancy (AFLP)
\end{itemize}
\end{itemize}
\item Metabolic Derangement
\label{sec:orgb2b3d4f}
\begin{itemize}
\item LCHAD is a component of MTP
\item bound to the inner mitochondrial membrane
\item activity is optimal for C12-C16
\item catalyzes dehydration of the 3-hydroxy group to a 3-keto group
(Figure \ref{fig:orgf6be80b})
\end{itemize}
\begin{figure}[htbp]
\centering
\includegraphics[width=0.6\textwidth]{fao/figures/lchad.png}
\caption{\label{fig:orgf6be80b}LCHAD reaction}
\end{figure}

\item Genetics
\label{sec:orgc0ff4e5}
\begin{itemize}
\item AR HADHA
\end{itemize}

\item Diagnostic Tests
\label{sec:org41167a2}
\begin{itemize}
\item \(\uparrow\) lactate \(\because\) 3-OH-palmitoyl-CoA inhibits PDH
\item \(\uparrow\) hydroxy-acylcarnitines
\begin{itemize}
\item \(\uparrow\) C14OH, C16OH, C18OH, C18:1OH
\end{itemize}
\item \(\uparrow\) UOA C6-C14 dicarboxylic and hydroxy-dicarboxylic acids
\end{itemize}

\item Treatment
\label{sec:org0e71c94}
\begin{itemize}
\item avoid fasting
\item low fat diet with MCT
\end{itemize}
\end{enumerate}
\subsubsection{Long-Chain Acyl-CoA Dehydrogenase Deficiency}
\label{sec:org8881737}
\begin{itemize}
\item LCAD is one of four mitochondrial acyl-CoA dehydrogenases that
catalyze the initial steps in the \(\beta\)-oxidation of fatty acids
(Table \ref{tab:orgb4d806f})
\item the substrate specificity of LCAD overlaps with that of
VLCAD and MCAD
\begin{itemize}
\item role  in  human  metabolism  is unclear
\end{itemize}
\item no human disease causing mutations have been identified
\end{itemize}

\subsubsection{Medium-Chain Acyl-CoA Dehydrogenase Deficiency}
\label{sec:org958454a}
\begin{enumerate}
\item Clinical Presentation
\label{sec:orgbbcbd14}
\begin{itemize}
\item most common FAOD with an incidence of approximately 1:10,000-20,000
in Europe, USA and Australia
\item before NBS, presented 4 months to 4 years
\begin{itemize}
\item acute hypoglycaemic encephalopathy and liver dysfunction, not always
\item some deteriorated rapidly and died
\end{itemize}
\item precipitated by prolonged fasting or infection with vomiting
\item some babies still present within 72 hours of birth before
newborn screening results are available
\begin{itemize}
\item hypoglycaemia and/or arrhythmias
\item breast-fed babies are at higher risk, due to the small supply of
breast milk at this stage
\end{itemize}
\item MCAD deficiency only presents clinically if exposed to an
appropriate environmental stress
\begin{itemize}
\item prior to NBS \textasciitilde{} 30-50\% remained asymptomatic
\end{itemize}
\item with NBS and preventative measures hypoglycaemia is rare
\begin{itemize}
\item patients do not develop cardiomyopathy or myopathy and few present
initially as adults
\end{itemize}
\item healty MCAD deficient children > 1 year can fast for 12-14 hours without problems
\begin{itemize}
\item >14 hours \(\to\) hypoketotic hypoglycaemia
\end{itemize}
\item shorter fasts may cause problems in infancy
\item encephalopathy may occur without hypoglycaemia
\begin{itemize}
\item accumulation of FFA acids and carnitine/CoA esters
\end{itemize}
\end{itemize}
\item Metabolic Derangement
\label{sec:orge17ad7f}
\begin{itemize}
\item MCAD is one of four mitochondrial acyl CoA dehydrogenases that
catalyze the initial steps in the \(\beta\)-oxidation of fatty acids
(Table \ref{tab:orgb4d806f})
\item MCAD accepts fatty-acyl-CoAs 6-12 carbons in length
\end{itemize}

\item Genetics
\label{sec:org6a4dc94}
\begin{itemize}
\item AR ACADM
\end{itemize}
\item Diagnostic Tests
\label{sec:org99d6142}
\begin{itemize}
\item plasma acylcarnitines
\begin{itemize}
\item \(\uparrow\) C8, C6, C10
\item \(\uparrow\) C8/C10
\end{itemize}
\item urine OA
\begin{itemize}
\item \(\uparrow\) C6-C10 dicarboxylic acids
\begin{description}
\item[{MCAD}] C8 > C6 > C10
\item[{MCT}] C10 > C8 > C6
\end{description}
\item \(\uparrow\) suberylglycine
\item \(\uparrow\) hexanolyglyine
\end{itemize}
\end{itemize}

\item Treatment
\label{sec:orgf2cd6bd}
\begin{itemize}
\item avoid fasting
\item low fat diet in infants
\end{itemize}
\end{enumerate}

\subsubsection{Short-Chain Acyl-CoA Dehydrogenase Deficiency}
\label{sec:orgd50cad0}
\begin{itemize}
\item non-disease
\begin{itemize}
\item previous association with symptoms due to ascertainment bias
\end{itemize}
\end{itemize}

\subsubsection{3-Hydroxyacyl-CoA Dehydrogenase Deficiency}
\label{sec:orgb059772}
\begin{itemize}
\item HADH previously called SCHAD deficiency, causes hyperinsulinaemic
hypoglycaemia
\item role in modulation of ATP production inhibition of GDH
\item see Congenital Hyperinsulinemia
\end{itemize}
\subsection{Electron Transfer Defects}
\label{sec:orgd1b70ae}
\subsubsection{Multiple Acyl-CoA Dehydrogenase Deficiency}
\label{sec:org7c736bf}
\begin{itemize}
\item AKA Glutaric Aciduria Type 2
\end{itemize}
\begin{enumerate}
\item Clinical Presentation
\label{sec:orgd21712c}
\begin{itemize}
\item ETF and ETFQO deficiencies \(\to\) wide range of clinical severity
\item severely affected patients present in the first few days of life
\begin{itemize}
\item hypoglycaemia, hyperammonaemia and acidosis
\item hypotonia and hepatomegaly
\end{itemize}
\item usually an odour of sweaty feet similar to that in IVA
\item some patients have congenital anomalies
\begin{itemize}
\item large cystic kidneys, hypospadias and neuronal migration defects and facial dysmorphism
\begin{itemize}
\item low set ears, high forehead and midfacial hypoplasia
\end{itemize}
\end{itemize}
\item malformations resemble those seen in CPTII deficiency but the pathogenesis is unknown
\item most patients with neonatal presentation die within a week of birth
\item others develop cardiomyopathy and die within a few months
\item less severe cases can present at any age from infancy to adulthood
\begin{itemize}
\item hypoglycaemia, liver dysfunction and weakness
\item usually precipitated by an infection
\end{itemize}
\item cardiomyopathy is common in infants
\item mildly affected children may have recurrent bouts of vomiting
\item muscle weakness is the commonest presentation in adolescents and adults
\begin{itemize}
\item predominantly affects proximal muscles and may lead to scoliosis,
hypoventilation or an inability to lift the chin off the chest
\end{itemize}
\item weakness can worsen rapidly during infection or pregnancy, myoglobinuria is rare
\end{itemize}

\item Metabolic Derangement
\label{sec:org3f5fc16}
\begin{itemize}
\item \textbf{electron transfer flavoprotein (ETF) and ETF ubiquinone}
\textbf{oxidoreductase (ETF-QO)} carry electrons to the respiratory chain
from multiple FAD-linked dehydrogenases
\item includes enzymes of amino acid, choline, \(\beta\)-oxidation, and ETC
\begin{description}
\item[{isovaleryl-CoA dehydrogenase}] \(\therefore\) \(\uparrow\) C5-carnitine, 3-hydroxyisovaleric acid
\item[{acyl-CoA dehydrogenases}] \(\therefore\) \(\uparrow\) C4-C18
\item[{CII}] \(\therefore\) \(\uparrow\) succinate
\item[{isobutyryl-CoA dehydrogenase}] \(\therefore\) \(\uparrow\) C4-carnitine, isobutyrylglycine
\item[{glutaryl-CoA dehydrogenase}] \(\therefore\) \(\uparrow\) C5DC-carnitine, 3-hydroxyglutaric acid
\item[{FAD-linked 2-hydroxyglutarate dehydrogenase}] \(\therefore\) \(\uparrow\) 2-hydroxyglutaric acid
\end{description}

\item MADD less often, a result of defects of riboflavin transport or
metabolism
\end{itemize}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.9\textwidth]{fao/figures/madd.png}
\caption{\label{fig:orgc1e3460}Multiple Acyl-CoA Dehydrogenase Deficiency}
\end{figure}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.9\textwidth]{fao/figures/etf.png}
\caption{\label{fig:org3078460}Role of ETF and ETF-QO}
\end{figure}

\item Genetics
\label{sec:org8e0785a}
\begin{itemize}
\item AR ETFA, ETFB, ETFDH
\end{itemize}

\item Diagnostic Tests
\label{sec:org0fa11d9}
\begin{itemize}
\item plasma acylcarnitines
\begin{itemize}
\item \(\uparrow\) C4-C18
\end{itemize}
\item urine OA
\begin{itemize}
\item \(\uparrow\) lactic
\item \(\uparrow\) glutaric
\item \(\uparrow\) 2-hydroxyglutaric
\item \(\uparrow\) 3-hydroxyisovaleric
\item \(\uparrow\) ethylmalonic
\item \(\uparrow\) dicarboxylic acids
\end{itemize}
\end{itemize}
\item Treatment
\label{sec:orga41bc76}
\begin{itemize}
\item avoid fasting
\item low fat diet
\item many milder defects respond to riboflavin
\end{itemize}
\end{enumerate}
\section{Pyruvate}
\label{sec:orgcc35632}
\subsection{Introduction}
\label{sec:orga38e911}
\begin{itemize}
\item pyruvate is formed from:
\begin{itemize}
\item glucose and other monosaccharides
\item lactate
\item gluconeogenic amino acid alanine
\end{itemize}
\item after entering mitochondria pyruvate can be converted into
acetyl-CoA by the pyruvate dehydrogenase complex, followed by
further oxidation in the TCA cycle
\end{itemize}

\begin{center}
\chemnameinit{}
\chemname{\chemfig{-[7](=[6]O)-[1](=[2]O)-[7]OH}}{pyruvate}
\hspace{20}
\chemnameinit{}
\chemname{\chemfig{-[7](=[6]O)-[1]S-[,,,,decorate, decoration=snake]CoA}}{acetyl-CoA}
\end{center}

\begin{itemize}
\item pyruvate can also enter the gluconeogenic pathway by
\begin{itemize}
\item conversion into oxaloacetate by pyruvate carboxylase
\item conversion to phosphoenolpyruvate by phosphoenolpyruvate carboxykinase
\end{itemize}
\item acetyl-CoA can also be formed by fatty acid oxidation or used for
lipogenesis
\end{itemize}


\subsubsection{Disorders of Pyruvate Metabolism}
\label{sec:org375e2bc}
\begin{itemize}
\item Pyruvate Carboxylase Deficiency
\item Phospoenolpyruvate Carboxykinase Deficiency
\item Pyruvate Dehydrogenase Complex Deficiency
\begin{itemize}
\item Dihydrolipoamide Dehydrogenase Deficiency (PDHC E3)
\end{itemize}
\item Pyruvate Transporter Defect
\end{itemize}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.7\textwidth]{pyruvate/figures/pyruvate_disorders.png}
\caption[TCA]{\label{fig:org28348b5}Disorders of Pyruvate Metabolism}
\end{figure}


\begin{figure}[htbp]
\centering
\includegraphics[width=0.9\textwidth]{pyruvate/figures/Slide13.png}
\caption[TCA]{\label{fig:org245f0fe}Pyruvate Metabolism and the TCA Cycle}
\end{figure}

\subsubsection{Reactions involving Pyruvate}
\label{sec:org626bf9c}

\begin{description}
\item[{pyruvate dehydrogenase complex}] decarboxylation \(\to\) acetyl-CoA
\end{description}

\ce{pyruvate + CoA + NAD+ <=>[PDHC] acetyl-CoA + CO2 + NADH + H+}

\begin{description}
\item[{pyruvate carboxylase}] carboxylation \(\to\) oxaloacetate
\end{description}

\ce{pyruvate + ATP + CO2 <=>[PC] oxaloacetate + ADP +Pi}

\begin{description}
\item[{alanine transaminase}] transamination \(\to\) alanine
\end{description}

\ce{pyruvate + glutamate <=>[ALT] alanine + \alpha-ketoglutarate}

\begin{description}
\item[{lactate dehydrogenase}] reduction \(\to\) lactate
\end{description}

\ce{pyruvate + NADH <=>[LDH] lactate + NAD+}

\subsection{Pyruvate Carboxylase Deficiency}
\label{sec:orgd0dbbdf}
\begin{itemize}
\item PC is a biotinylated mitochondrial matrix enzyme
\begin{itemize}
\item carboxylation of pyruvate to oxaloacetate
\end{itemize}

\ce{pyruvate + ATP + CO2 ->[PC] oxaloacetate + ADP + Pi}

\item important role in:
\begin{itemize}
\item gluconeogenesis
\begin{itemize}
\item urea cycle indirectly
\begin{itemize}
\item oxaloacetate \(\to\) aspartate used by ASS
\end{itemize}
\end{itemize}
\item anaplerosis
\begin{itemize}
\item \(\downarrow\) 2-ketoglutarate \(\to\) \(\downarrow\) glutamate
\item \(\downarrow\) TCA intermediates lowers reducing equivalents
\begin{itemize}
\item redox equilibrium between 3-OH-butyrate and acetoacetate \(\to\) acetoacetate
\item \(\downarrow\) 3-OH-butyrate/acetoacetate ratio
\end{itemize}
\end{itemize}
\item lipogenesis
\begin{itemize}
\item oxaloacetate + acetyl-CoA \(\to\) citrate
\end{itemize}
\end{itemize}

\item PC requires biotin and bicarbonate
\item metabolic derangements associated with PC are observed in:
\begin{itemize}
\item biotin deficiency, biotinidase deficiency and HCS deficiency
\item three important biotin-dependent carboxylases:
\begin{itemize}
\item propionyl-CoA carboxylase (PCC)
\item 3-methylcrotonyl-CoA carboxylase (MCC)
\item pyruvate carboxylase (PC)
\end{itemize}

\item CAVA deficiency
\begin{itemize}
\item results in dysfunction of all four enzymes (three above and
CPS1) to which CAVA provides bicarbonate as substrate in
mitochondria (see Urea Cycle)
\end{itemize}
\end{itemize}
\end{itemize}

\subsubsection{Clinical Presentation}
\label{sec:org042a92b}
\begin{itemize}
\item French phenotype (type B) most severe
\begin{itemize}
\item acute illness 3-48hrs after birth
\item hypothermia, hypotonia, lethargy, vomiting
\item severe neurological dysfunction
\item death prior to 5 months
\end{itemize}
\item American phenotype (type A)
\begin{itemize}
\item severe illness between 2 and 5 months of age
\item progressive hypotonia
\item acute vomiting, dehydration, tachypnoea, metabolic acidosis
\item severe intellectual disability
\item progressive with death in infancy
\end{itemize}
\item benign phenotype (type c)
\begin{itemize}
\item rare
\item acute episodes of lactic acidosis and ketoacidosis
\item near normal cognitive and motor development
\end{itemize}
\end{itemize}
\subsubsection{Genetics}
\label{sec:org4b7448a}
\begin{itemize}
\item AR PC 1:250000
\item PC is a homo-tetramer
\item PC protein and mRNA absent in 50\% of French phenotype
\item American and benign phenotypes have cross-reacting material
\item mosaicism has been observed with prolonged survival
\end{itemize}

\subsubsection{Diagnostic Tests}
\label{sec:orgc25e67d}
\begin{itemize}
\item PC deficiency should be considered in any child presenting with
lactic acidosis and neurological abnormalities
\begin{itemize}
\item \(\uparrow\) lactate and pyruvate
\item hypoglycemia, hyperammonemia, or ketosis
\end{itemize}
\item N-\(\uparrow\) L/P with \(\downarrow\) \(\beta\)-hydroxybutyrate/acetoacetate
seen in severely affected patients
\begin{itemize}
\item pathognomonic in neonates
\end{itemize}
\item post-prandial ketosis, hypercitrullinemia, hyperammonemia, low glutamine
\begin{itemize}
\item \(\because\) \(\downarrow\) TCA, \(\downarrow\) AAS and \(\downarrow\) \(\alpha\)-KG
\end{itemize}
\item CSF lactate, alanine and L/P are elevated, glutamine decreased
\item PC activity in cultured skin fibroblasts
\begin{itemize}
\item can not distinguish severity
\end{itemize}
\end{itemize}

\subsubsection{Treatment}
\label{sec:org416d4c4}
\begin{itemize}
\item none
\end{itemize}

\subsection{Phospoenolpyruvate Carboxykinase Deficiency}
\label{sec:orgb286dd9}
\begin{itemize}
\item PEPCK has cytosolic and mitochondria isoforms
\item cytosolic PEPCK deficiency is secondary to hyperinsulinism
\begin{itemize}
\item insulin represses expression of the cytosolic form
\end{itemize}
\item mitochondrial PEPCK deficiency has not been clearly demonstrated
\end{itemize}

\subsection{Pyruvate Dehydrogenase Complex Deficiency}
\label{sec:org77b075f}
\begin{itemize}
\item PDHC decarboxylates pyruvate \(\to\) acetyl-CoA
\begin{itemize}
\item thiamine dependent
\end{itemize}
\item PDHC, KDHC and BCKD have similar structure and mechanism
\item composed of:
\begin{itemize}
\item E1 \(\alpha\)-ketoacid dehydrogenase
\item E2 dihydrolipoamide acyltransferase
\item E3 dihydrolipoamide dehydrogenases
\end{itemize}
\item E1 is specific to each complex
\begin{itemize}
\item composed of E1\(\alpha\) and E1\(\beta\)
\end{itemize}
\item E1 is the rate limiting step in PDHC
\begin{itemize}
\item regulated by phosphorylation
\end{itemize}
\end{itemize}

\begin{table}[htbp]
\caption{\label{tab:orgc4e52b4}Pyruvate Dehydrogenases Complex}
\centering
\begin{tabular}{llll}
Unit & Name & Gene & Cofactor\\
\hline
E1\(\alpha\) & pyruvate dehydrogenase & PDHA1 & thiamine pyrophosphate\\
E1\(\beta\) &  & PDHB & \\
E2 & dihydrolipoyl  S-acetyltransferase & DLAT & lipoate, CoA\\
E3 & dihydrolipoyl dehydrogenase & DLD & FAD, NAD\textsuperscript{+}\\
\end{tabular}
\end{table}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.6\textwidth]{pyruvate/figures/pdhe1_phos.png}
\caption[pdhe1]{\label{fig:org0de32a4}Activation/Deactivation of PDH E1}
\end{figure}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.7\textwidth]{pyruvate/figures/pdhc.png}
\caption[pdhc]{\label{fig:orga8991a6}Pyruvate Dehydrogenase Complex}
\end{figure}

\begin{itemize}
\item PDHC deficiency provokes conversion of pyruvate to lactate and alanine rather than acetly-CoA
\item metabolism of glucose \(\to\) lactate, produces 1/10 ATP compared to
complete oxidation via TCA and ETC
\item impairs production of NADH but not oxidation
\item NADH/\ce{NAD+} is normal \(\therefore\) N-\(\downarrow\) L/P
\begin{itemize}
\item ETC deficiencies \(\to\) \(\uparrow\) L/P
\end{itemize}
\end{itemize}

\subsubsection{Clinical Presentation: PDH E1\(\alpha\)}
\label{sec:org564a859}
\begin{itemize}
\item majority of cases involve the X encoded \(\alpha\)-subunit of the dehydrogenase (E1)
\begin{itemize}
\item PDH E1\(\alpha\) deficiency
\item developmental delay, hypotonia, seizures and ataxia
\end{itemize}

\item common presentations in hemizygous males:
\begin{enumerate}
\item neonatal lactic acidosis
\begin{itemize}
\item most severe
\end{itemize}
\item \textbf{Leigh's encephalopathy}
\begin{itemize}
\item most common
\item present in first 5 years
\end{itemize}
\item intermittent ataxia
\begin{itemize}
\item rare
\item ataxia after carbohydrate rich meals \(\to\) Leigh's syndrome
\end{itemize}
\end{enumerate}

\item females with PDH E1\(\alpha\), uniform presentation, variable severity
\begin{itemize}
\item dismorphic features
\item moderate to severe intellectual disability
\item seizures common
\item severe neonatal lactic acidosis can be present
\end{itemize}
\end{itemize}

\subsubsection{Clinical Presentation: PDH E1\(\beta\)}
\label{sec:orgc37b7ea}
\begin{itemize}
\item very rare
\item similar to PDH E1\(\alpha\)
\end{itemize}

\subsubsection{Genetics}
\label{sec:orgc3b02e0}
\begin{itemize}
\item all components of PDHC are encoded by nuclear genes
\item autosomal except E1\(\alpha\) on Xp22.11
\begin{itemize}
\item \textbf{\(\therefore\) most PDHC deficiency is X-linked}
\begin{itemize}
\item has semi-dominant inheritance
\end{itemize}
\end{itemize}
\item no null E1\(\alpha\) identified except in a mosaic state
\begin{itemize}
\item suggests E1\(\alpha\) is essential
\end{itemize}
\end{itemize}

\subsubsection{Diagnostic Tests}
\label{sec:org3ff4a54}
\begin{itemize}
\item \(\uparrow\) lactate and pyruvate in blood and CSF
\begin{itemize}
\item CSF lactate \textgreater{} blood lactate
\end{itemize}
\item urine organic acids
\begin{itemize}
\item \(\uparrow\) lactic and pyruvate
\end{itemize}
\item plasma amino acids
\begin{itemize}
\item \(\uparrow\) alanine
\end{itemize}
\item L/P ratio is usually normal
\item skin fibroblasts for PDHC
\begin{itemize}
\item also lymphocytes, separated from EDTA <2days
\end{itemize}
\item PDHE1\(\alpha\) genotype in females is useful
\end{itemize}

\subsubsection{Treatment}
\label{sec:org35ac927}
\begin{itemize}
\item early adoption of ketogenic diet may have a benefit
\item thiamine responsive forms
\item dichloroacetate is a pyruvate analog, inhibits E1 kinase, keeps E1
dephosphorylated (active) (Figure \ref{fig:org0de32a4})
\end{itemize}

\subsubsection{Pyruvate Transport Defect}
\label{sec:org16735d9}
\begin{itemize}
\item MPC1 mutations have been described in 5 patients
\item mediates the proton symport of pyruvate across the IMM
\item \(\therefore\) metabolic derangement similar to PDHC deficiency
\item no treatment
\end{itemize}

\subsection{Dihydrolipoamide Dehydrogenase Deficiency}
\label{sec:org35d0d6a}
\begin{itemize}
\item DLD (E3) is a flavoprotein common to all three mitochondrial
\(\alpha\)-ketoacid dehydrogenase complexes
\begin{itemize}
\item PDHC, KDHC, and BCKD
\item combined PDHC, TCA, BCAA defect
\end{itemize}
\end{itemize}
\subsubsection{Genetics}
\label{sec:org2aa6a29}
\begin{itemize}
\item AR DLD
\end{itemize}
\subsubsection{Diagnostic Testing}
\label{sec:orgd9a96d9}
\begin{itemize}
\item combined PDHC, KDHC, BCKDH defect
\begin{itemize}
\item \(\uparrow\) lactate, pyruvate
\item \(\uparrow\) alanine, glutamate, glutamine, BCAA
\item urine OA
\begin{itemize}
\item \(\uparrow\) lactic, pyruvic (PDH)
\item \(\uparrow\) 2-ketoglutaric (KGDH)
\item \(\uparrow\) 2-hydroxyisovaleric (BCKDH)
\item \(\uparrow\) 2-oxoisocaproic (BCKDH)
\end{itemize}
\end{itemize}
\item pattern of abnormalities not seen in all patients at all times
\end{itemize}
\section{Tricarboxylic Acid Cycle}
\label{sec:orga5cd52f}
\subsection{Introduction}
\label{sec:org430be72}
\begin{itemize}
\item pathways for oxidation of fatty acids, glucose, amino acids and
ketones produce acetyl-CoA which can enter the TCA cycle
\item one molecule of glucose breaks down into two molecules of pyruvate
\item pyruvate is converted into acetyl-CoA which is the main TCA input
\item release of energy via oxidation of acetly-CoA
\item primary function of the TCA cycle is to generate reducing
equivalents in the form of NADH and FADH\textsubscript{2}
\begin{itemize}
\item used to produce ATP in the electron transport chain
\end{itemize}
\end{itemize}

\begin{center}
\chemnameinit{}
\chemname{\chemfig{-[7](=[6]O)-[1]S-[,,,,decorate, decoration=snake]CoA}}{acetyl-CoA}
\end{center}

\begin{itemize}
\item part of aerobic respiration
\begin{itemize}
\item ETC regenerates
\begin{itemize}
\item \ce{NAD+} via oxidization of NADH
\item FAD via oxidization of FADH\textsubscript{2}
\end{itemize}
\end{itemize}
\item cofactors:
\begin{itemize}
\item niacin (\ce{NAD+})
\item riboflavin (FAD and FMN)
\item panthothenic acid (CoA)
\item thiamine
\item \ce{Mg^2+}, \ce{Ca^2+}, \ce{Fe+} and phosphate
\end{itemize}
\item TCA net reaction
\end{itemize}

{\scriptsize\ce{Acetyl-CoA + 3NAD+ + FAD + GDP + Pi + 2H2O -> 2CO2 + CoA + 3NADH + FADH2 + GTP + 2H+}}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.9\textwidth]{tca/figures/Slide13.png}
\caption[TCA]{\label{fig:orgd82f5d8}Pyruvate Metabolism and the TCA Cycle}
\end{figure}

\subsubsection{Disorders of the TCA cycle}
\label{sec:org9c4df91}

\begin{itemize}
\item \(\alpha\)-Ketoglutarate Dehydrogenase Complex Deficiency
\item Succinate Dehydrogenase Deficiency
\item Fumarase Deficiency
\end{itemize}

\subsection{\(\alpha\)-Ketoglutarate Dehydrogenase Complex Deficiency}
\label{sec:orgb25a65a}
\begin{itemize}
\item KDHC is a \(\alpha\)-ketoacid dehydrogenase analogous to PDHC and BCKD
\end{itemize}

\ce{\alpha-ketoglutarate + NAD+ + CoA ->[KDHC] succinyl-CoA + CO2 + NADH}

\begin{table}[htbp]
\caption{\label{tab:org9465495}\(\alpha\)-Ketoglutarate Dehydrogenase Complex}
\centering
\begin{tabular}{llll}
Unit & Name & Gene & Cofactor\\
\hline
E1 & \(\alpha\)-ketoglutarate dehydrogenase & OGDH & thiamine pyrophosphate\\
E2 & dihydrolipoyl succinyltransferase & DLST & lipoic acid, CoA\\
E3 & dihydrolipoyl dehydrogenase & DLD & FAD, NAD\textsuperscript{+}\\
\end{tabular}
\end{table}

\begin{itemize}
\item E1 subunit is the thiamine dependant substrate specific dehydrogenase
\begin{itemize}
\item not regulated by phosphorylation
\end{itemize}
\item E2 subunit dihydrolipyoyl succinyl-transferase is also specific to KDHC
\end{itemize}

\subsubsection{Clinical Presentation}
\label{sec:org6063f48}
\begin{itemize}
\item similar to PDHC (section \ref{sec:org77b075f})
\item developmental delay, hypotonia, opisthotonos and ataxia
\begin{itemize}
\item seizures less common
\end{itemize}
\item present as neonate and early childhood
\end{itemize}

\subsubsection{Genetics}
\label{sec:org0264181}
\begin{itemize}
\item AR OGDH, DLST, DLD
\end{itemize}

\subsubsection{Diagnostic Tests}
\label{sec:org30dcd9b}
\begin{itemize}
\item urine organic acids
\begin{itemize}
\item \(\uparrow\) \(\alpha\)-KGA \textpm{} other TCA intermediates
\item \(\alpha\)-KGA is a common finding, not specific for KDHC deficiency
\end{itemize}
\item blood lactate
\begin{itemize}
\item N-\(\uparrow\) L/P
\end{itemize}
\item KDHC activity
\begin{itemize}
\item \ce{^14CO2} release from \ce{[1-^14C]} \(\alpha\)-ketoglutarate (or \ce{[1-^14C]} leucine)
\item cultured skin fibroblasts
\item muscle
\end{itemize}
\end{itemize}

\subsubsection{Treatment}
\label{sec:org87ca019}
\begin{itemize}
\item none
\end{itemize}
\subsection{Succinate Dehydrogenase Deficiency}
\label{sec:org81c5bf9}
\begin{itemize}
\item four subunits compose Complex II of the mitochondrial respiratory
chain (Table \ref{tab:org2dbd493})
\end{itemize}

\begin{table}[htbp]
\caption{\label{tab:org2dbd493}Succinate Dehydrogenase | Complex II}
\centering
\begin{tabular}{ll}
Subunit & Description\\
\hline
SdhA & succinate dehydrogenase flavoprotein subunit\\
SdhB & succinate dehydrogenase iron-sulfur subunit\\
SdhC & succinate dehydrogenase cytochrome b560 subunit\\
SdhD & succinate dehydrogenase cytochrome b small subunit\\
\end{tabular}
\end{table}

\begin{itemize}
\item SdhA contains an FAD binding site where succinate is deprotonated
and converted to fumarate
\end{itemize}

\ce{succinate + ubiquinone(Q) ->[CII] fumarate + ubiquinol(QH2)}

\begin{itemize}
\item electrons removed from succinate transfer to SdhA
\item transfer across SdhB through iron sulphur clusters to the SdhC/SdhD subunits
\begin{itemize}
\item SdhC/SdhD are anchored in the mitochondrial membrane
\end{itemize}
\end{itemize}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.5\textwidth]{tca/figures/SuccDeh.png}
\caption{\label{fig:org973492f}Succinate Dehydrogenase | Complex II}
\end{figure}

\subsubsection{Clinical Presentation}
\label{sec:org8e38c03}
\begin{itemize}
\item very rare disorder with highly variable phenotype
\item Complex II is part of the TCA cycle and ETC
\begin{itemize}
\item phenotype resembles defects in respiratory chain
\end{itemize}
\item clinical picture can include:
\begin{itemize}
\item Kearns-Sayre syndrome
\item isolated hypertrophic cardiomyopathy
\item combined cardiac and skeletal myopathy
\item generalized muscle weakness, \(\uparrow\) fatigue
\item early onset Leigh encephalopathy
\end{itemize}
\item also:
\begin{itemize}
\item cerebral ataxia
\item optic atropy
\item tumour formation in adults
\end{itemize}
\end{itemize}

\subsubsection{Genetics}
\label{sec:orgae79b1c}
\begin{itemize}
\item AR with highly variable phenotype
\item all components of Complex II are encoded by nuclear DNA (Table \ref{tab:org418728d})
\item mutations in SDHB, SDHC and SDHD cause susceptibility to familial
phaeochromocytoma and familial paraganglioma
\end{itemize}

\begin{table}[htbp]
\caption{\label{tab:org418728d}Succinate Dehydrogenase Genetics}
\centering
\begin{tabular}{ll}
Gene & Location\\
\hline
SDHA & 5p15.33\\
SDHB & 1p36.13\\
SDHC & 1q23.3\\
SDHD & 11q23.1\\
\end{tabular}
\end{table}

\subsubsection{Diagnostic Tests}
\label{sec:orgb853615}
\begin{itemize}
\item unlike other TCA cycle disorders Complex II deficiency does not always
result in characteristic organic aciduria
\begin{itemize}
\item succinic aciduria
\end{itemize}
\item organic acids can show variable amounts of lactate, pyruvate, succinate, fumarate and malate
\item measurement of complex II activity in muscle is the most reliable
means of diagnosis
\begin{itemize}
\item no clear correlation between residual complex II activity and
severity or clinical outcome
\end{itemize}
\end{itemize}
\subsubsection{Treatment}
\label{sec:orgc9544b7}
\begin{itemize}
\item in some cases treatment with riboflavin may have clinical benefit
\end{itemize}

\subsection{Fumarase Deficiency}
\label{sec:org6fca5c2}
\begin{itemize}
\item fumarase (AKA fumarate hydratase) catalyses reversible
hydration/dehydration of fumarate to malate
\end{itemize}
\ce{fumarate + H2O <=>[FH] malate}
\begin{itemize}
\item two forms: mitochondrial and cytosolic
\begin{itemize}
\item mitochondrial isoenzyme is involved in the TCA Cycle
\item cytosolic isoenzyme is involved in the metabolism of amino acids and fumarate
\end{itemize}
\item subcellular localization is established by the presence/absence of an N-terminal mitochondrial signal
sequence
\item deficiency causes impaired energy production
\end{itemize}

\subsubsection{Clinical Presentation}
\label{sec:orgbc5f710}
\begin{itemize}
\item characterized by polyhydramnios and fetal brain abnormalities
\item newborn period findings include:
\begin{itemize}
\item severe neurologic abnormalities
\item poor feeding
\item failure to thrive
\item hypotonia
\end{itemize}
\item fumarase deficiency is suspected in infants with multiple severe
neurologic abnormalities in the absence of an acute metabolic crisis
\item inactivity of both cytosolic and mitochondrial forms of fumarase are
potential causes
\end{itemize}
\subsubsection{Genetics}
\label{sec:org4a88730}
\begin{itemize}
\item AR FH encoded by nuclear DNA
\item single gene and mRNA encode mito and cyto isoforms
\end{itemize}
\subsubsection{Diagnostic Tests}
\label{sec:orge67bc92}
\begin{itemize}
\item isolated increased concentration of fumaric acid on urine organic
acid analysis is highly suggestive of fumarase deficiency
\begin{itemize}
\item succinate, \(\alpha\)-KGA can also be elevated
\end{itemize}
\item molecular genetic testing for fumarase deficiency
\end{itemize}
\subsection{Isocitrate Dehydrogenase}
\label{sec:org3e20ff1}
\begin{itemize}
\item IDH exists in three isoforms:
\begin{itemize}
\item IDH3 catalyzes the third step of the citric acid cycle
\end{itemize}
\end{itemize}
\ce{isocitrate + NAD+ ->[IHD3] \alpha-ketoglutarate + CO2 + NADH + H+}
\begin{itemize}
\item IDH1 and IDH2 catalyze the same reaction outside TCA cycle and
uses \ce{NADP+} as a cofactor
\begin{itemize}
\item localize to the cytosol as well as mitochondria and peroxisomes
\end{itemize}
\end{itemize}
\ce{isocitrate + NADP+ ->[IHD1/2] \alpha-ketoglutarate + CO2 + NADPH + H+}

\subsubsection{Clinical Presentation}
\label{sec:org48d5ec7}
\begin{itemize}
\item IDH3 deficiency is associated with retinitis pigmentosa
\item IDH1/2 mutations linked to malignant gliomas and acute myeloid leukemia
\end{itemize}
\section{Oxidative Phosphorylation}
\label{sec:org4f6997e}
\subsection{Introduction}
\label{sec:org545da06}
\begin{itemize}
\item oxidative phosphorylation is the process in which ATP is formed as a
result of the transfer of electrons from NADH or FADH\textsubscript{2} to O\textsubscript{2} by a
series of electron carriers (Figures \ref{fig:org90b6c48} and \ref{fig:org299f66d})
\item responsible for ATP production
\item ETC complexes I-IV
\item OxPhos system complexes I-V
\item \textasciitilde{} 90 subunits
\item 13 subunits of complexes I, III, IV and V encoded by mtDNA (Table \ref{tab:orgc5d7d89})
\item \textgreater{} 1500 proteins in the human mitochondrial proteome
\item up to 10\% of human proteome may have role in maintaining mitochondrial function
\item OxPhos requires mitochondrial functions for:
\begin{itemize}
\item protein import, turnover
\item fission, fusion
\item mtDNA replication, transcription and translation
\begin{itemize}
\item \textgreater{} 200 proteins, rRNAs and tRNAs
\end{itemize}
\item cofactors: coenzyme Q\textsubscript{10}, iron-sulfur clusters, heme, copper
\item cardiolipin for cristae formation
\end{itemize}

\item ETC and OxPhos are coupled by a proton gradient across the IMM
\begin{itemize}
\item efflux of protons from the mitochondrial matrix creates an
electrochemical gradient
\begin{itemize}
\item used by the F\textsubscript{0}F\textsubscript{1} ATP synthase complex to make ATP via oxidative phosphorylation
\end{itemize}
\end{itemize}
\item energy from transfer of electrons down the ETC is used to pump
protons from the mitochondrial matrix into the intermembrane space
\begin{itemize}
\item creates an electrochemical proton gradient (\(\Delta\)pH) across the IMM
\begin{itemize}
\item largely responsible for the mitochondrial membrane potential (\(\Delta \Psi\)M)
\end{itemize}
\item ATP synthase uses flow of \ce{H+} through the enzyme back into the
matrix to generate ATP from ADP and Pi
\end{itemize}
\item three energy-transducing enzymes in the electron transport chain:
\begin{itemize}
\item NADH:ubiquinone oxidoreductase (CI)
\item Coenzyme Q  cytochrome c reductase (CIII)
\item Cytochrome c oxidase (CIV)
\end{itemize}
\end{itemize}


\begin{figure}[htbp]
\centering
\includegraphics[width=1.1\textwidth]{./oxphos/figures/etc.pdf}
\caption{\label{fig:org90b6c48}Flow of Electrons in the ETC}
\end{figure}

\begin{itemize}
\item Complex I (NADH coenzyme Q reductase) accepts electrons from the
Krebs cycle electron carrier NADH
\item passes them to CoQ (ubiquinone)
\item CoQ also receives electrons from CII, GDP and ETF-QO

\item CoQ passes electrons to complex III (cytochrome bc1 complex) which
passes them to cytochrome c
\item cytochrome c passes electrons to Complex IV (cytochrome c oxidase)
which uses the electrons and hydrogen ions to reduce molecular
oxygen to water

\item ETF-QO and mitochondrial glycerol-3-P dehydrogenase (GPD) are part of ETC (Figure \ref{fig:org90b6c48})
\begin{itemize}
\item pass electrons to CoQ
\end{itemize}
\end{itemize}

\begin{table}[htbp]
\caption{\label{tab:orgc5d7d89}Location of DNA Encoding OxPhos Complex Subunits}
\centering
\begin{tabular}{lrlrrr}
 & CI & CII & CIII & CIV & CV\\
\hline
mtDNA & 7 & \textbf{0} & 1 & 3 & 2\\
nDNA & 39 & 4 & 10 & 10 & 14\\
\end{tabular}
\end{table}

\begin{figure}[htbp]
\centering
\includegraphics[width=\textwidth]{oxphos/figures/Slide14.png}
\caption[ETC]{\label{fig:org299f66d}Oxidative Phosphorylation}
\end{figure}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.6\textwidth]{oxphos/figures/potential.png}
\caption[redox]{\label{fig:org94675d8}Electron Flow to O\textsubscript{2} and Release of Free Energy}
\end{figure}

\subsubsection{Complex I}
\label{sec:org3619556}
\begin{itemize}
\item AKA NADH-ubiquinone oxidoreductase
\item catalyzes the transfer of electrons from NADH to CoQ and
translocates protons across the inner mitochondrial membrane
\end{itemize}

{\small\ce{NADH + H+ + CoQ + 4H^{+}_{in} ->[CI] NAD+ + CoQH2 + 4H^{+}_{out}}}

\begin{itemize}
\item mechanism: 
\begin{enumerate}
\item seven iron sulfur centers carry electrons from the site of NADH
oxidation to ubiquinone (Figure \ref{fig:org950151e})
\item ubiquinone (CoQ) is reduced to ubiquinol (\ce{CoQH2})
\item the energy from the redox reaction results in conformational
change allowing hydrogen ions to pass through four transmembrane
helix channels
\end{enumerate}
\end{itemize}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.9\textwidth]{./oxphos/figures/c1.pdf}
\caption[c1]{\label{fig:org950151e}Complex I | NADH-Ubiquinone Oxidoreductase}
\end{figure}

\subsubsection{Complex II}
\label{sec:org14af092}
\begin{itemize}
\item AKA Succinate Dehydrogenase 
\begin{itemize}
\item see section \ref{sec:org81c5bf9}
\end{itemize}
\end{itemize}

\subsubsection{Glycerol-3-Phosphate Shuttle}
\label{sec:org0c243fb}
\begin{itemize}
\item oxidation of cytoplasmic NADH by the cytosolic form of the enzyme
creates glycerol-3-phosphate from dihydroxyacetone phosphate
\item glycerol-3-phosphate diffuses into IMM and is oxidised by mitochondrial glycerol-3-phosphate dehydrogenase
\begin{itemize}
\item uses quinone as an oxidant and FAD as a co-factor
\end{itemize}
\item maintains the cytoplasmic NAD\textsuperscript{+}/NADH ratio
\end{itemize}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.6\textwidth]{oxphos/figures/GPDH_shuttle.png}
\caption[g3ps]{\label{fig:orgac96d9d}Glycerol-3-Phosphate Shuttle}
\end{figure}

\subsubsection{Electron Transferring Flavoprotein/ Dehydrogenase}
\label{sec:orgcf370d2}
\begin{itemize}
\item ETFs are heterodimeric proteins composed of an \(\alpha\) and \(\beta\)
subunit (ETFA and ETFB)
\begin{itemize}
\item contain an FAD cofactor and AMP
\end{itemize}
\item ETQ-QO links the oxidation of fatty acids and some amino acids to
oxidative phosphorylation in the mitochondria
\item catalyzes the transfer of electrons from electron transferring
flavoprotein (ETF) to ubiquinone reducing it to ubiquinol
\end{itemize}

{\small\ce{Acyl-CoA + FAD ->[ACAD] FADH2 + ETF ->[ETF-QO] CoQ ->[CIII] CytC}}

\begin{itemize}
\item ETF-QO deficiency results in \textbf{Glutaric Acidemia Type 2} (AKA MADD)
\begin{itemize}
\item see section FAODs
\end{itemize}
\end{itemize}
\subsubsection{Complex III}
\label{sec:org384d502}
\begin{itemize}
\item AKA Coenzyme Q Cytochrome C Reductase
\item Complex III is a multi-subunit transmembrane protein encoded by both
mitochondrial (cytochrome B) and the nuclear genomes (all other
subunits)

\begin{itemize}
\item Complex III contains 11 subunits:
\begin{itemize}
\item 3 respiratory subunits (cytochrome B, cytochrome C1, Rieske protein)
\item 2 core proteins
\item 6 low-molecular weight proteins
\end{itemize}
\end{itemize}

{\small\ce{QH2 + 2Fe^{3+}-cytC + 2H+_{in} ->[CIII]  Q + 2Fe^{2+}-cytC + 4H+_{out}}}
\end{itemize}

\subsubsection{Complex IV}
\label{sec:org11a1bb5}
\begin{itemize}
\item AKA Cytochrome c oxidase
\item last enzyme in the respiratory electron transport chain
\item large IMM integral membrane protein composed of several metal prosthetic sites and 14 protein subunits
\item eleven subunits are nuclear in origin, and three are synthesized in the mitochondria
\begin{itemize}
\item contains two hemes, cytochrome A and cytochrome A3
\item two copper centers, CuA and CuB
\item cytochrome a3 and CuB form a binuclear center that is the site of
oxygen reduction
\item receives an electron from four cytochrome C molecules and
transfers them to one O\textsubscript{2} molecule
\end{itemize}

{\small\ce{4Fe^{2+}-cytC + 8H^{+}_{in} + O2 ->[CIV] 4Fe^{3+}-cytC + 2H2O + 4H^{+}_{out}}}

\begin{itemize}
\item binds four protons from the inner aqueous phase to make two water
molecules
\item translocates another four protons across the membrane
\end{itemize}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.5\textwidth]{oxphos/figures/CIV.png}
\caption[cIV]{\label{fig:orgd17f34c}Complex IV | Cytochrome C Oxidase}
\end{figure}
\end{itemize}

\subsubsection{Complex V}
\label{sec:orgc3f5b42}
\begin{itemize}
\item AKA ATP synthase
\item ATP synthase is a molecular machine that creates ATP
\item overall reaction catalyzed by ATP synthase is:
\end{itemize}

{\small\ce{ADP + P_i + H+_{out} <=>[CV] ATP + H2O + H+_{in}}}

\begin{itemize}
\item formation of ATP from ADP and P\textsubscript{i} is energetically unfavourable
\begin{itemize}
\item would normally proceed in the reverse direction
\end{itemize}

\item to drive this reaction forward, ATP synthase couples ATP synthesis
to the electrochemical gradient (\(\Delta \Psi\)M) created by complexes
I, III and IV
\item ATP synthase consists of two main subunits, F\textsubscript{0} and F\textsubscript{1},
\begin{itemize}
\item a rotational motor mechanism \(\to\) ATP production

\begin{figure}[htbp]
\centering
\includegraphics[width=0.5\textwidth]{oxphos/figures/atp_synthase.jpg}
\caption{\label{fig:org5ce4770}Complex V | ATP Synthase}
\end{figure}
\end{itemize}
\end{itemize}

\subsection{Clinical Presentation}
\label{sec:org0473c20}
\begin{itemize}
\item molecular pathogenesis of OxPhos disorders (Figure \ref{fig:orga699b6d})
\begin{enumerate}
\item OxPhos complexes or assembly - Leigh Syndrome (COX assembly)
\item mtDNA maintainance - MDDS, MELAS (POLG)
\item mitochondrial translation - MIDD (MT-TL)
\item CoQ biosynthesis - CoQ deficiency
\item mitochondrial protein import - TOM and TIM
\item mitochondrial solute import - PEO (ANT1)
\item mitochondrial membrane lipid synthesis - Barth (TAZ)
\item motility of mitochondrial membranes - MEGDEL (SERAC1)
\end{enumerate}
\end{itemize}

\begin{figure}[htbp]
\centering
\includegraphics[width=\textwidth]{oxphos/figures/Slide15.png}
\caption[ETC]{\label{fig:orga699b6d}Pathogenesis of OxPhos Disorders}
\end{figure}


\begin{figure}[htbp]
\centering
\includegraphics[width=0.9\textwidth]{oxphos/figures/mtDNA_disorders.png}
\caption{\label{fig:org756794d}mtDNA Disorders}
\end{figure}

\begin{itemize}
\item clinical diagnosis is extremely challenging
\begin{itemize}
\item can affect any organ system
\item antenatal (IUGR, birth defects) \(\to\) elderly (myopathy)
\end{itemize}

\item clinical suspicion based on:
\begin{enumerate}
\item constellation of symptoms/signs consistent with a mitochondrial syndrome (Table \ref{tab:org9dc7ad2})
\item complex multi-system presentation involving two/more organ systems,
best described by an underlying disorder of energy generation
\item lactic acidosis, characteristic neuro-imaging, 3-methylglutaconic
aciduria, ragged red fiber mypopathy
\item pathogenic mutation in a known mitochondrial disease gene
\end{enumerate}
\end{itemize}

\begin{table}[htbp]
\caption{\label{tab:org9dc7ad2}Clinical Features of Mitochondrial Disease}
\centering
\begin{tabular}{ll}
System & Manifestation\\
\hline
CNS & \textbf{myoclonus} (muscle jerks)\\
 & \textbf{seizures}, \textbf{ataxia}\\
 & encephalopathy\\
 & strokes, GDD\\
 & peripheral neuropathy\\
Skeletal muscle & \textbf{myopathy, hypotonia}\\
 & rhabdomyolysis\\
Marrow & sideroblastic anemia/pancytopenia\\
Kidney & Fanconi\\
Endocrine & \textbf{diabetes}\\
 & hypoparathyroidism\\
 & growth/multiple hormone deficiency\\
Heart & cardiomyopathy\\
 & conduction defects\\
GI & pancreatic failure\\
 & villous atrophy\\
Ear & \textbf{sensorineural deafness}\\
Eye & \textbf{PEO}, ptosis, RP\\
Systemic & \textbf{lactic acidosis}, hypoglycemia\\
 & IUGR, FTT\\
\end{tabular}
\end{table}


\begin{enumerate}
\item Neonatal and Infantile Presentation
\label{sec:org7cbe9de}
\begin{enumerate}
\item \textbf{Barth}
\label{sec:orge39616b}
\begin{itemize}
\item cardiomyopathy, myopathy
\begin{description}
\item[{XL}] TAZ
\end{description}
\item Tafazzin catalyzes the remodeling of the acyl chains of immature
cardiolipin to a mature, predominantly tetralinoleylcardiolipin
\end{itemize}
\item \textbf{Leigh Syndrome}
\label{sec:orgab06e82}
\begin{itemize}
\item AKA: subacute necrotising encephalopathy
\item most frequent presentation of MD in childhood
\item degeneration of CNS
\item bilateral symetrical lesions on MRI
\item GDD, growth retardation
\item hypo/er-ventilation, spasticity, dystonia, ataxia, tremor, optic atrophy
\item cardiomyopathy, renal tubulopathy, GI disfunction
\item \textgreater{} 75 genes(mt and nuclear)
\begin{description}
\item[{mtDNA}] MT-ATP6 and other
\item[{AR}] SURF1, SDHA, COX assembly, CI
\item[{XL}] PDHA1 (PDHC E1\(\alpha\) subunit)
\end{description}
\item Saguenay-Lac-St-Jean type incidence 1/2000, carriers 1/23
\item several biochemical defects including: PDHC, OxPhos
\item \(\uparrow\) lactate blood and CSF
\end{itemize}
\item \textbf{MEGDEL}: 3-Methylglutaconic aciduria, Deafness, Encephalopathy and Leigh-like Disease
\label{sec:org45b21d0}
\begin{itemize}
\item phosphatidylglycerol remodeling protein found at the interface of
mitochondria and ER
\item mediates phospholipid exchange
\begin{description}
\item[{AR}] SERAC1
\end{description}
\end{itemize}
\item \textbf{Pearson's marrow-pancreas syndrome}
\label{sec:org8dd4f6f}
\begin{itemize}
\item transfusion dependent sideroblastic anemia/pancytopenia
\item exocrine pancreas failure
\item progressive liver disease
\item renal tubular disease
\begin{description}
\item[{mtDNA}] large del/dup sporadic
\end{description}
\end{itemize}
\item \textbf{MDDS}: mitochondrial DNA depletion syndrome
\label{sec:org058ec3c}
\begin{itemize}
\item hepatocerebral disease
\item progressive myopathy
\item \(\downarrow\) CI, CIII, and CIV activity (mtDNA)
\item N/\(\uparrow\) CII activity (nDNA)
\begin{description}
\item[{AR}] POLG, DGUOK, twinkle, SUCLA2, TK
\end{description}
\end{itemize}
\item \textbf{Alpers syndrome}
\label{sec:org47ae2fb}
\begin{itemize}
\item progressive neuronal degradation of childhood
\item seizures
\begin{description}
\item[{AR}] POLG
\end{description}
\end{itemize}
\item \textbf{Reversible infantile respiratory chain deficiency}
\label{sec:orgf594fc5}
\begin{itemize}
\item protein translation defect
\item glutamic acid tRNA
\begin{description}
\item[{mtDNA}] MT-TE
\end{description}
\end{itemize}
\item \textbf{CoQ deficiency}
\label{sec:org114297f}
\begin{itemize}
\item multisystem involvement including neurologic manifestations
\begin{itemize}
\item fatal neonatal encephalopathy with hypotonia
\item late-onset slowly progressive multiple-system atrophy
\begin{description}
\item[{mtDNA}] COQ genes
\end{description}
\end{itemize}
\end{itemize}
\end{enumerate}
\item Childhood and Adolescent Presentation
\label{sec:org07b4ec1}
\begin{enumerate}
\item \textbf{Kearns-Sayre Syndrome}
\label{sec:org8d40723}
\begin{itemize}
\item subtype of CPEO w earlier onset \textless{} 20
\item progressive external opthalmoplegia (PEO)
\item pigmentary retinopathy
\item cardiac conduction defect
\item ataxia, \(\uparrow\) CSF protein
\item isolated limb myopathy
\begin{description}
\item[{mtDNA}] deletions \textpm{} duplications
\item[{AR}] RRM2B
\end{description}
\end{itemize}
\item \textbf{MELAS}: Myopathy, Encephalopathy, Lactic Acidosis, Stroke-like Episodes
\label{sec:org542fcf7}
\begin{itemize}
\item most common mito encephalopathy
\item RRF, PEO
\begin{description}
\item[{mtDNA}] 80\%
\item[{AR}] POLG
\end{description}
\end{itemize}
\item \textbf{MERRF}: myoclonic epilepsy w ragged red fibres
\label{sec:orgfb2abf0}
\begin{itemize}
\item ptosis (drooping eyelids), ataxia, deafness
\begin{description}
\item[{mtDNA}] MT-TK, others
\end{description}
\end{itemize}
\item \textbf{NARP}: neuropathy, ataxia, retinitis pigmentosa
\label{sec:orga9ec85f}
\begin{description}
\item[{mtDNA}] MT-ATP6
\end{description}
\item \textbf{LHON}: Lebers Hereditary Optic Neuropathy
\label{sec:org2cc3a55}
\begin{itemize}
\item most common cause of blindness in otherwise healthy young men
\begin{itemize}
\item males \textgreater{} females 4:1
\end{itemize}
\item maternally inherited and manifests in late adolescence or early
adulthood as bilateral sequential visual failure
\item 90\% of patients are affected by age 40
\begin{description}
\item[{mtDNA}] MT-ND1, MT-ND4, MT-ND6
\end{description}
\end{itemize}
\item \textbf{MNGIE}: Mitochondrial Neuro-Gastro-Intestinal Encephalopathy
\label{sec:orgc36e740}
\begin{itemize}
\item demyelinating neuropathy
\item leukoencephalopathy
\item \(\uparrow\) plasma \& urine thymidine and deoxyuridine
\begin{description}
\item[{AR}] TYMP
\end{description}
\end{itemize}
\end{enumerate}
\item Adult Presentation
\label{sec:orgdcae969}
\begin{enumerate}
\item \textbf{MIDD}: maternally inherited diabetes and deafness
\label{sec:orga1dc78d}
\begin{description}
\item[{mtDNA}] MT-TL1
\end{description}
\item \textbf{CPEO}: Chronic Progressive External Ophthalmoplegia
\label{sec:org109b0e8}
\begin{itemize}
\item progressive external ophthalmoplegia
\begin{itemize}
\item inability to move eyes and eyebrows
\end{itemize}
\item ptosis - drooping or falling eyelids
\item mtDNA quantitation in muscle biopsy is diagnostic
\begin{description}
\item[{mtDNA}] deletions \textpm{} duplications
\end{description}
\end{itemize}

\item \textbf{SANDO}: Sensory Ataxic Neuropathy, dysarthria and opthalmoparesis
\label{sec:org5974d36}
\begin{description}
\item[{AR}] POLG
\end{description}
\end{enumerate}
\end{enumerate}

\subsection{Metabolic Derangement}
\label{sec:org29dd56c}
\begin{itemize}
\item insufficient ATP severely affects highly energy dependant tissues
\begin{itemize}
\item a complete loss of OxPhos is not observed in human disease
\end{itemize}
\item in the absence of OxPhos cells survive using ATP from anaerobic glycolysis
\begin{itemize}
\item 20x less efficient generates lactate
\end{itemize}
\item lactate, pyruvate and alanine are the typical products of anaerobic glycolysis
\end{itemize}

\subsection{Diagnostic Tests}
\label{sec:org0a80df5}
\begin{figure}[htbp]
\centering
\includegraphics[width=1.2\textwidth]{oxphos/figures/algorithm_rot.png}
\caption{\label{fig:org0b9d99c}Diagnosis of Mitochondrial Disease}
\end{figure}


\subsubsection{Biochemistry}
\label{sec:orgba6502d}
\begin{itemize}
\item none of the following are specific for OxPhos disorders
\item \(\uparrow\) blood lactate, CSF lactate
\item \(\uparrow\) L/P at rest \(\Uparrow\) after exercise
\item renal tubular dysfunction: urine anion gap, pH, serum K
\end{itemize}
\begin{enumerate}
\item plasma amino acids:
\label{sec:orgb2e1955}
\begin{itemize}
\item alanine \(\propto\) pyruvate
\begin{itemize}
\item \(\uparrow\) alanine \textgreater{} 450 uM
\item \(\uparrow\) alanine/lysine \textgreater{} 3:1
\item \(\uparrow\) alanine/(phenylalanine + tyrosine) \textgreater{} 4:1
\end{itemize}
\item \(\uparrow\) glycine in lipoic acid biosynthesis defects
\item \(\uparrow\) proline due to \(\downarrow\) proline oxidase activity
\item \(\downarrow\) citrulline and arginine in Leigh, NARP, MELAS and Pearson
\end{itemize}
\item urine amino acids:
\label{sec:org3998bba}
\begin{itemize}
\item aminoaciduria in renal Fanconi
\begin{itemize}
\item mtDNA deletions
\end{itemize}
\end{itemize}
\item urine organic acids:
\label{sec:org8a1a5ca}
\begin{itemize}
\item lactate, pyruvate, TCA intermediates
\begin{itemize}
\item renal immaturity \(\to\) \(\uparrow\) TCA intermediates
\end{itemize}
\item 3-methylglutaconic acid in Barth, Sengers, MEGDEL, ATP synthase deficiency
\item ethylmalonic
\item MMA in succinyl-CoA ligase deficiency
\item dicarboxylic aciduria
\end{itemize}
\item plasma acylcarnitines
\label{sec:org06165b1}
\begin{itemize}
\item flavin cofactor metabolism
\end{itemize}
\item purine and pyrimidines (plasma or urine)
\label{sec:org4366700}
\begin{itemize}
\item MNGIE \(\uparrow\) thymidine and deoxyuridine
\end{itemize}
\begin{itemize}
\item FGF-21, GDF15 and creatinine \(\propto\) mito disfunction in myopathy
\end{itemize}

\item L/P ratio
\label{sec:orgdaae15a}
\begin{description}
\item[{PDHC}] N-\(\downarrow\)
\item[{TCA}] N-\(\uparrow\)
\item[{ETC}] \(\uparrow\)
\end{description}
\item OxPhos subunit activity
\label{sec:org2b1a721}
\begin{itemize}
\item CII is encoded by nuclear DNA (Table \ref{tab:orgc5d7d89})
\begin{itemize}
\item \(\therefore\) not affected by mtDNA depletion
\end{itemize}
\item CoQ deficiency results in:
\begin{itemize}
\item \(\downarrow\) combined CI + CIII activity
\item \(\downarrow\) combined CII + CIII activity
\item normal individual CI, CII, and CII activity
\end{itemize}
\end{itemize}
\end{enumerate}

\subsubsection{Imaging}
\label{sec:orga7f0411}
\begin{itemize}
\item cranial CT shows cerebral and cerebellar atrophy in many encephalopathic patients
\begin{itemize}
\item basal ganglia calcification may be seen in MELAS
\end{itemize}
\item MRI in MELAS-associated stroke reveals increased T2 weighted signals in the grey and white matter
\item symmetrical changes in the basal ganglia and brainstem observed in Leigh syndrome
\end{itemize}

\subsubsection{Histology}
\label{sec:org307b824}
\begin{itemize}
\item biopsy of affected muscle is diagnostic
\begin{itemize}
\item mitochondrial myopathy due to mtDNA mutations and LHON may have normal biopsies
\end{itemize}
\item immunohistochemistry for COX (complex IV), SDH, complex V
\item ragged red fibres on Gomori trichrome staining, due to mitochondrial proliferation
\begin{itemize}
\item suggests mtDNA mutation
\item fibres stain strongly for succinate dehydrogenase
\item fibres often negative for COX (complex IV) in CPEO, KSS, and MERRF
but positive in MELAS
\item Leigh syndrome patients may have no ragged red fibres and
COX-negative fibres only
\end{itemize}
\end{itemize}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.5\textwidth]{oxphos/figures/Ragged_red_fibers_in_MELAS.jpg}
\caption[rrf]{\label{fig:orgd1ed72d}Ragged Red Fibers - Gomori Stain}
\end{figure}

\subsubsection{Molecular}
\label{sec:org02ea9da}
\begin{itemize}
\item no strict relation between phenotype and genotype
\item common mutation affect tRNAs, nucleotide metabolism, fusion
\item mtDNA tRNA mutations are most common of the single base change abnormalities
\begin{description}
\item[{MT-TP}] tRNA\textsuperscript{Pro}
\item[{MT-TL1}] tRNA\textsuperscript{Leu(UUR)}
\item[{MT-TK}] tRNA\textsuperscript{Lys}
\item[{Twinkle}] mtDNA helicase
\item[{POLG}] polymerase \(\gamma\)
\item[{TYMP}] thymidine phosphorylase
\item[{RRM2B}] ribonucleotide reductase
\item[{DGUOK}] deoxyguanosine kinase
\item[{ANT1}] adenine nucleotide translocase type 1
\item[{OPA1}] fusion
\end{description}
\end{itemize}

\subsection{Treatment}
\label{sec:org0e29de2}
\begin{description}
\item[{Coenzyme Q disorders}] high dose coenzyme Q
\item[{CI deficiency}] some are riboflavin responsive
\item vitamin and cofactor cocktails have limited evidence:
\begin{itemize}
\item coenzyme Q
\item thiamine (B\textsubscript{1})
\item riboflavin (B\textsubscript{2})
\end{itemize}
\end{description}
\section{Ketogenesis and Ketolysis}
\label{sec:org015b7b1}
\subsection{Introduction}
\label{sec:org4c8cc83}
\begin{itemize}
\item ketone bodies (KB) are an important fuel for many tissues including
cardiac and skeletal muscle during fasting
\item particularly important for the brain which cannot oxidise fatty
acids
\item principal KBs acetoacetate and 3-hydroxybutyrate are maintained in
equilibrium by \(\beta\)-hydroxybutyrate dehydrogenase

\ce{acetoacetate + NADH <=>[HBDH] \beta-hydroxybutyrate + NAD+}
\end{itemize}

\begin{center}
\chemnameinit{}
\chemname{\chemfig{H_3C-[1](=[2]O)-[7]CH_3}}{acetone}
\hspace{20}
\chemnameinit{}
\chemname{\chemfig{H_3C-[1](=[2]O)-[7]-[1](=[2]O)-[7]OH}}{acetoacetate}
\hspace{20}
\chemnameinit{}
\chemname{\chemfig{H_3C-[1](-[2]OH)-[7]-[1](=[2]O)-[7]OH}}{$\beta$-hydroxybutyrate}
\end{center}

\begin{itemize}
\item acetone is formed from acetoacetate non-enzymatically and eliminated in breath
\item formed in liver mitochondria from fatty acids and certain amino acids (e.g. leucine)
\item cross cell membranes by diffusion or facilitated by monocarboxylate transporter 1 (MCT1)
\begin{itemize}
\item MCT1 transport is important during catabolic stress, \(\uparrow\) flux
\end{itemize}
\item converted to acetyl-CoA in the mitochondria of extrahepatic tissues for use as fuel
\item one ketolytic enzyme, mitochondrial acetoacetyl-CoA thiolase (AKA
\(\beta\)-ketothiolase or T2) is also involved in isoleucine catabolism
\end{itemize}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.9\textwidth]{ketones/figures/ketones.png}
\caption{\label{fig:org2557914}Ketogenesis and Ketolysis}
\end{figure}

\begin{itemize}
\item disorders of ketone body metabolism present either in the first few
days of life or later in childhood, during an infection or some
other metabolic stress
\item the primary aim of treatment is to prevent decompensation
\item fasting is avoided and a high glucose intake is maintained at times
of metabolic stress such as infections
\end{itemize}

\subsection{Ketogenesis Defects}
\label{sec:org6cfa8bb}
\begin{itemize}
\item there are two defects of ketogenesis:
\begin{enumerate}
\item 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase deficiency
\item 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase deficiency
\end{enumerate}
\end{itemize}

\subsubsection{Clinical Presentation}
\label{sec:orged14c01}
\begin{table}[htbp]
\caption{\label{tab:org78b79f7}Common Manifestations in Ketogenesis Defects}
\centering
\begin{tabular}{llllll}
FAOD & sudden & fasting & skeletal & cardio- & liver\\
 & death & intolerance & myopathy & myopathy & disease\\
\hline
HMGCS & \(\uparrow\) & \(\Uparrow\) & rare & rare & \(\Uparrow\)\\
HMGCL & rare & \(\Uparrow\) & \(\uparrow\) & \(\uparrow\) & rare\\
\end{tabular}
\end{table}

\begin{enumerate}
\item HMG-CoA Synthase Deficiency
\label{sec:orge481f97}
\begin{itemize}
\item presents with hypoglycaemia
\begin{itemize}
\item often accompanied by coma and metabolic acidosis
\item precipitated by infections with vomiting or poor feeding in early
childhood (5 months to 6 years of age)
\end{itemize}
\item usually hepatomegaly, which resolves
\item hyperammonaemia is rare, (surprisingly) ketonuria may be present
\item most patients recover with intravenous glucose
\end{itemize}

\item HMG-CoA Lyase Deficiency
\label{sec:org63aef83}
\begin{itemize}
\item presents with hypoglycaemia, metabolic acidosis, vomiting and a
reduced level of consciousness
\item 30\% patients, the onset is within 5 days of birth, after a short symptom-free period
\item \textasciitilde{}70\% patients, symptoms are provoked by an infection in the first year
\item few patients present later, occasionally as adults
\item KB levels are inappropriately low blood lactate concentrations
may be markedly elevated, particularly in neonatal onset cases
\item often hyperammonaemia, hepatomegaly and abnormal liver function tests and
may develop pancreatitis or cardiomyopathy
\item neurological sequelae include:
\begin{itemize}
\item epilepsy, intellectual handicap, hemiplegia or cerebral visual loss
\item magnetic resonance imaging (MRI) shows diffuse mild signal changes
in the cerebral white matter on T2-weighted images with multiple
foci of more severe signal abnormality
\end{itemize}
\item myelination may be impaired because KB are a substrate for the
synthesis of myelin cholesterol
\end{itemize}
\end{enumerate}

\subsubsection{Metabolic Derangement}
\label{sec:org423d3c1}
\begin{itemize}
\item KB are synthesised in hepatic mitochondria, primarily using
acetyl-CoA derived from fatty acid oxidation
\item HMG-CoA synthase catalyses the condensation of acetoacetyl-CoA and
acetyl-CoA to form HMG-CoA, which is cleaved by HMG-CoA lyase to
release acetyl-CoA and acetoacetate

\ce{acetyl-CoA + acetoacetyl-CoA + H2O <=>[HMGCS] HMG-CoA + CoA}

\ce{HMG-CoA <=>[HMGCL] acetoacetate + acetyl-CoA}

\item HMG-CoA can also be derived from the leucine metabolite
3-methylglutaconyl-CoA
\item \textbf{HMG-CoA synthase and HMG-CoA lyase deficiencies both impair
ketogenesis}
\begin{itemize}
\item \textbf{HMG-CoA lyase deficiency also causes the accumulation of
intermediates of the leucine catabolic pathway}
\end{itemize}
\item lack of KB synthesis leads to excessive glucose consumption and
hypoglycaemia during fasting
\end{itemize}

\subsubsection{Genetics}
\label{sec:orgde1cab0}
\begin{itemize}
\item AR HMGCS2
\item AR HMGCL
\end{itemize}

\subsubsection{Diagnostic Tests}
\label{sec:org883839b}
\begin{itemize}
\item critical sample is important
\item if the plasma free fatty acid concentration is raised with an
inappropriately small rise in total KB it implies a defect of
ketogenesis or fatty acid oxidation 
\begin{itemize}
\item \(\Uparrow\) plasma FFA/total KB >2.5
\end{itemize}
\end{itemize}

\begin{enumerate}
\item HMG-CoA Synthase Deficiency
\label{sec:org5bfe006}
\begin{itemize}
\item normal metabolic studies when not fasting
\item during decompensation, urine contains saturated, unsaturated and
3-hydroxy-dicarboxylic acids, 5-hydroxyhexanoic acid and other
metabolites
\begin{itemize}
\item \(\uparrow\) 4-hydroxy-6-methyl-2-pyrone is the most specific
\end{itemize}
\item plasma acylcarnitines are normal when patients are well
\begin{itemize}
\item raised during illness
\end{itemize}
\item diagnosis is confirmed by mutation analysis
\end{itemize}

\item HMG-CoA Lyase Deficiency
\label{sec:org5b9568d}
\begin{itemize}
\item urine organic acids contain leucine metabolites
\begin{itemize}
\item \(\uparrow\) 3-hydroxy-3-methylglutaric (HMG)
\item \(\uparrow\) 3-hydroxyisovaleric
\item \(\uparrow\) 3-methylglutaconic
\item \(\uparrow\) 3-methylglutaric
\item 3-methylcrotonylglycine may also be present
\end{itemize}
\item plasma acylcarnitines
\begin{itemize}
\item \(\uparrow\) 3-hydroxyisovaleryl-carnitine (C5OH)
\item \(\uparrow\) 3-methylglutaryl-carnitine (C6DC)
\end{itemize}
\item diagnosis is confirmed by mutation analysis or measuring HMG-CoA
lyase activity in leukocytes or cultured fibroblasts
\end{itemize}
\end{enumerate}

\subsubsection{Treatment}
\label{sec:org91a8c05}
\begin{itemize}
\item avoid fasting and maintain  high carbohydrate intake during any
metabolic stress such as infections
\item IV glucose is required if no oral intake or vomiting
\end{itemize}
\begin{enumerate}
\item HMG-CoA Synthase Deficiency
\label{sec:orga16c5a7}
\begin{itemize}
\item HMG-CoA synthase deficiency has a good prognosis
\end{itemize}

\item HMG-CoA Lyase Deficiency
\label{sec:orgb7c0a87}
\begin{itemize}
\item IV sodium bicarbonate may be needed if there is severe acidosis
\item moderate protein restriction is usually recommended in HMG-CoA
lyase deficiency because of its role in leucine catabolism
\end{itemize}
\end{enumerate}

\subsection{Ketolysis Defects}
\label{sec:orgfaa0b5c}
\begin{itemize}
\item ketone body utilisation is catalysed by:
\begin{enumerate}
\item succinyl-CoA:3-oxoacid CoA transferase (SCOT)
\item mitochondrial acetoacetyl-CoA thiolase (T2)
\begin{itemize}
\item AKA \(\beta\)-ketothiolase or 3-oxothiolase
\end{itemize}
\end{enumerate}
\item SCOT, T2 or MCT1 deficiencies present with episodes of ketoacidosis
\end{itemize}

\subsubsection{Clinical Presentation}
\label{sec:org91ed7d2}
\begin{itemize}
\item patients present with episodes of severe ketoacidosis in early childhood
\item few patients have seizures or cardiomegaly at the time of presentation
\item patients are healthy between episodes, with normal blood pH
\item decompensation triggered by fasting or an infection with poor
feeding and vomiting
\item blood glucose, lactate and ammonia concentrations are usually normal
\end{itemize}

\subsubsection{Metabolic Derangement}
\label{sec:orgda1725a}
\begin{itemize}
\item KB utilisation occurs in extrahepatic mitochondria, starting with
the transfer of coenzyme A from succinyl-CoA to acetoacetate,
catalysed by SCOT

\ce{succinyl-CoA + acetoacetate <=>[SCOT] acetoacyl-CoA + succinate}

\item this forms acetoacetyl-CoA, which is converted to acetyl-CoA by T2
\item second reaction can also be catalysed to some extent by
medium-chain 3-ketoacyl-CoA thiolase (T1)
\begin{itemize}
\item may explain why T2 deficient patients do not have permanent
ketosis
\end{itemize}
\ce{acetoacetyl-CoA + CoA <=>[T2] 2\cdot acetyl-CoA}

\item SCOT is not expressed in liver and has no role other than
ketolysis
\item T2 is expressed in liver, involved in ketogenesis and ketolysis
\item patients with T2 deficiency present with ketoacidosis
\begin{itemize}
\item T2 more crucial in ketolysis than in ketogenesis
\end{itemize}
\item T2 also cleaves 2-methylacetoacetyl-CoA in the isoleucine
degradation pathway
\begin{itemize}
\item T2 deficiency \(\to\) \(\uparrow\) isoleucine-derived acyl-CoA esters
\item these may be responsible for neurodevelopmental abnormalities
\end{itemize}
\item ketoacidosis in patients with MCT1 deficiency \(\to\) transporters
facilitate rapid entry of KB at times of stress
\item MCT1 transporters are important for lactate transport
\begin{itemize}
\item expressed in the brain, particularly on oligodendroglia
\end{itemize}
\item learning difficulties in MCT1 deficient patients may be due to the
absence of MCT1 in the brain
\end{itemize}

\subsubsection{Genetics}
\label{sec:org12a9246}
\begin{itemize}
\item AR  OXCT1 (SCOT), ACAT1 (T2) and SLC16A1 (MCT1)
\item heterozygous SLC16A1 and OXCT1 mutations have been found in several
patients investigated for ketoacidosis, suggesting that they can
cause problems if subjects are exposed to sufficient stress

\item heterozygous SLC16A1 mutations can also cause hyperinsulinemia
\begin{itemize}
\item promoter mutations that prevent the normal silencing of MCT1
expression in pancreatic \(\beta\)-cells
\end{itemize}
\end{itemize}

\subsubsection{Diagnostic Tests}
\label{sec:org1346a6c}
\begin{enumerate}
\item SCOT \& MCT1 Deficiencies
\label{sec:orgb54628c}
\begin{itemize}
\item \(\downarrow\) plasma FFA/total KB <0.3 suggests a defect of ketolysis
\end{itemize}
\begin{itemize}
\item urine organic acids show \(\uparrow\) KB but no specific abnormalities
\item patients with severe SCOT deficiency have persistent ketonuria in
the fed state, but patients with a mild mutation do not
\item diagnoses are now usually made by mutation analysis
\end{itemize}

\item T2 Deficiency
\label{sec:orgf49027d}
\begin{itemize}
\item urine OA - \(\uparrow\) leucine metabolites
\begin{itemize}
\item \(\uparrow\) 2-methylacetoacetate
\begin{itemize}
\item 2-methylacetoacetate is unstable
\end{itemize}
\item \(\uparrow\) 2-methyl-3-hydroxybutyric acid
\item \(\uparrow\) tiglylglycine
\end{itemize}

\item patient with mild mutations may only show abnormalities when they
are stressed (e.g isoleucine load)
\item 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency causes a
similar pattern of organic acids but 2-methyacetoacetate is not excreted
\item plasma acylcarnitines
\begin{itemize}
\item \(\uparrow\) 2-methyl-3-hydroxybutyrylcarnitine (C5OH)
\begin{itemize}
\item isobaric with 3-hydroxyisovalerylcarnitine
\end{itemize}
\item \(\uparrow\) tiglylcarnitine (C5:1)
\item may be normal with mild mutations
\end{itemize}
\item diagnosis must be confirmed by mutation analysis or enzyme assay in fibroblasts
\begin{itemize}
\item assays are complicated by the presence of other thiolases that act
on acetoacetyl-CoA
\end{itemize}
\end{itemize}
\end{enumerate}

\subsubsection{Treatment}
\label{sec:org69d8a43}
\begin{itemize}
\item same as ketogenesis defects above
\item T2 involved in isoleucine metabolism \(\therefore\) \(\downarrow\) protein intake
\end{itemize}
\section{Creatine}
\label{sec:org6b090f7}
\subsection{Introduction}
\label{sec:org80c9256}
\begin{itemize}
\item creatine is synthesized by two enzymatic reactions:
\begin{enumerate}
\item arginine:glycine amidinotransferase (AGAT) catalyses the
transfer of an amidino group from arginine to glycine, yielding
guanidinoacetate
\item guanidinoacetate methyltransferase (GAMT) catalyses the
methylation of the amidino group in the guanidinoacetate
molecule, yielding creatine
\end{enumerate}

\item creatine synthesis occurs mainly, but not exclusively, in the kidney
and in the pancreas, which have high AGAT activity, and in the
liver, which has high GAMT activity

\item from these organs of synthesis creatine is transported via the
bloodstream to the organs of utilization, mainly muscle and brain
\begin{itemize}
\item taken up by a sodium and chloride dependent creatine transporter
(CRTR)
\end{itemize}

\item most brain creatine is transported from the blood via CRTR expressed
at blood-brain barrier
\item a minor proportion is synthesized in the brain

\item part of intracellular creatine is reversibly converted into the
high-energy compound creatine-phosphate by creatine kinase (CK)

\item creatine and creatine-phosphate are non-enzymatically converted into
creatinine

\item creatinine is mainly excreted in urine and its daily excretion is
directly proportional to total body creatine, and in particular to
muscle mass
\end{itemize}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.9\textwidth]{creatine/figures/creatine.png}
\caption{\label{fig:org79d2f32}Metabolic Pathway of Creatine/Creatine Phosphate}
\end{figure}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.9\textwidth]{creatine/figures/Slide16.png}
\caption{\label{fig:org9ec0fd2}Metabolic Pathway of Creatine/Creatine Phosphate}
\end{figure}

\subsection{Creatine Deficiency Syndromes}
\label{sec:org7b4fd59}
\begin{itemize}
\item creatine deficiency syndromes (CDS) are a group of inborn errors of:
\item creatine synthesis
\begin{itemize}
\item \textbf{arginine:glycine amidinotransferase (AGAT)} deficiency
\item \textbf{guanidinoacetate methyltransferase (GAMT)} deficiency
\end{itemize}
\item creatine transport
\begin{itemize}
\item X-linked \textbf{creatine transporter (CRTR)} deficiency
\end{itemize}
\item global developmental delay/ intellectual disability along with
various neurological manifestations

\item secondary changes in creatine metabolism have been described in
disorders affecting arginine, ornithine and methionine metabolism including:
\begin{itemize}
\item ornithine aminotransferase (OAT) deficiency
\item urea cycle defects
\item hyperammonemia, hyperornithinemia, homocitrullinuria (HHH) syndrome
\item \(\Delta\)1-pyrroline-5-carboxylate synthetase (P5CS) deficiency
\item methylcobalamin synthesis defects
\item mitochondrial disease
\end{itemize}
\end{itemize}

\subsubsection{Clinical Presentation}
\label{sec:org3aa6d5f}
\begin{itemize}
\item global developmental delay (GDD) or intellectual disability (ID)
\begin{itemize}
\item with prominent speech delay
\end{itemize}
\item GDD or ID ranges from mild to severe and is characteristically
associated with challenging (hyperactive, autistic) behaviours
\item distinguishing symptoms:
\begin{description}
\item[{AGAT}] myopathy
\item[{GAMT}] movement disorders and basal ganglia changes are
additional features
\item[{GAMT \& CRTR}] epilepsy
\end{description}
\end{itemize}

\subsubsection{Metabolic Derangement}
\label{sec:orgeb0f562}
\begin{itemize}
\item cerebral creatine deficiency is caused by reduced synthesis of
creatine in AGAT and GAMT deficiency or by impaired uptake into the
brain in CRTR deficiency
\item low intracellular creatine and creatine-phosphate result in reduced
production of creatinine
\begin{itemize}
\item \(\therefore\) \(\downarrow\) urine and plasma creatinine
\end{itemize}
\item guanidinoacetate is neurotoxic \(\to\) CNS
\begin{itemize}
\item \(\downarrow\) AGAT deficiency
\item \(\uparrow\) GAMT deficiency
\end{itemize}
\end{itemize}

\subsubsection{Genetics}
\label{sec:org5432aae}
\begin{itemize}
\item AR GATM (AGAT)  and GAMT (GAMT)
\item X-linked SLC6A8 (CRTC)
\end{itemize}
\subsubsection{Diagnostic Tests}
\label{sec:org2bb9d79}
\begin{itemize}
\item MRS to screen for cerebral creatine deficiency
\item urine guanidinoacetate, creatine and creatinine is an important
screening test for all CDS (Table \ref{tab:org8e97b93})
\item CSF guanidinoacetate
\begin{itemize}
\item \(\uparrow\) in GAMT \(\sim\) 100x normal
\end{itemize}
\end{itemize}



\begin{table}[htbp]
\caption{\label{tab:org8e97b93}Urine Findings in CDS}
\centering
\begin{tabular}{lll}
 & GAA & creatine/creatinine\\
\hline
AGAT & \(\downarrow\) & N/\(\downarrow\)\\
GAMT & \(\Uparrow\) & \(\downarrow\)\\
CRTR & N & \(\uparrow\)\\
\end{tabular}
\end{table}

\subsubsection{Treatment}
\label{sec:orgdb1ca84}
\begin{itemize}
\item normal neurodevelopmental outcome has been reported in early treated
patients with creatine synthesis defects
\item AGAT and GAMT treated with creatine monohydrate
\item GAMT deficiency - reduction of guanidinoacetate is achieved by
ornithine supplementation \textpm{} dietary arginine restriction
\begin{itemize}
\item arginase ERT to \(\downarrow\) arginine and \(\uparrow\) ornithine
\end{itemize}
\item CRTC no treatment
\item CRTR deficiency - creatine, arginine and glycine supplementation
does not significantly improve outcome, although partial clinical
improvement has been reported in single patients
\end{itemize}
\end{document}